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ABSTRACT 
Thanks to continuous technical advances in the sequencing field nowadays we know 
that most of the mammalian genome is transcribed. This generates a vast repertoire of 
transcripts that includes protein-coding messenger RNAs (mRNAs), long non-coding 
RNAs (lncRNAs) and repetitive sequences, such as Short Interspersed Nuclear 
Elements (SINEs). A large percentage of ncRNAs is nuclear-enriched with unknown 
function. LncRNAs may be transcribed in antisense direction and may form 
sense/antisense pairs by pairing with an mRNA from the opposite strand to regulate 
chromatin conformation, transcription and mRNA stability. 
We have identified a nuclear-enriched lncRNA antisense to mouse Ubiquitin 
Carboxyterminal Hydrolase L1 (Uchl1), a gene expressed in dopaminergic cells and 
involved in brain function and neurodegenerative diseases. Antisense Uchl1 (AS 
Uchl1) increases Uchl1 protein synthesis at a post-transcriptional level. AS Uchl1 
function is under the control of stress signaling pathways, as mTORC1 inhibition by 
rapamycin causes an increase in Uchl1 protein that is associated to the shuttling of AS 
Uchl1 lncRNA from the nucleus to the cytoplasm of dopaminergic cells. AS Uchl1 
RNA is then required for the association of the overlapping sense protein-coding 
mRNA to active polysomes for translation. 
Moreover, AS Uchl1 activity depends on the presence of a 5’ domain overlapping 
Uchl1 mRNA and an inverted SINEB2 element embedded along its 3’ sequence. 
These features are shared by other natural antisense transcripts and among them a 
lncRNA antisense to Ubiquitously eXpressed Transcript (AS Uxt) increases Uxt 
protein expression in the presence of stable mRNA level similar to AS Uchl1. These 
data identified a new functional class of lncRNAs and reveal another layer of gene 
expression control at the post-transcriptional level. 
Furthermore, through the replacement of AS Uchl1 5’ overlapping region with an 
antisense sequence to Green Fluorescence Protein (GFP) we were able to redirect this 
upregulation of protein synthesis. In fact, the presence of a 5’ overlapping sequence 
and an embedded inverted SINEB2 element confer to this artificial AS lncRNA to 
GFP (AS GFP) the capability to induce GFP protein with stable mRNA levels both in 
cells and in vitro translation assay. Further experiments are needed to set up the in 
vitro translation assay and to understand the translation enhancement of AS lncRNAs. 
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INTRODUCTION 
From the beginning of the genetic age the relationship between DNA content and 
biological complexity has been an interesting subject of discussion. Defining 
biological complexity as a combination of metabolic and developmental complexity, 
in terms of number, types, and organization of cells in an organism, there is generally 
a close relationship between genome size and genetic capacity in the prokaryotes. In 
contrast, there are major incongruities between both cellular DNA content and the 
number of protein-coding genes in relation to developmental complexity in the 
eukaryotes, whose genomes contain large amounts of non-protein-coding sequences 
(Taft et al., 2007). 
Evidence from numerous high-throughput genomic platforms suggests that the 
evolution of developmental processes regulating the complexity of the organism is 
mainly due to the expansion of regulatory potential of the noncoding portions of the 
genome (Mattick, 2004). 
Moreover, genome sequence comparisons have shown that multicellular organisms 
exhibit significant conservation of non-protein-coding DNA, indicating that these 
sequences have genetic function (Dermitzakis, 2003). 
These observations suggest that there may be a vast hidden layer of RNA regulatory 
information. Indeed, since the establishment of the concept of messenger RNAs 
(mRNAs), numerous regulatory RNAs which do not code for protein have been 
discovered. 
 
 
Non-Coding RNAs 
Insights into the transcriptional landscape of the human genome, based in part on the 
work of the international FANTOM Consortium, have revealed that more than 70% 
of the genome is transcribed (The FANTOM Consortium, 2005), whereas less than 
2% is subsequently translated (Bertone et al., 2004; Cheng et al., 2005; Kapranov et 
al., 2005). In accordance with this observation, the more recent work of the ENCODE 
Consortium has indicated that at least 80% of the human genome is transcribed, 
resulting in the generation of a large number of non-coding RNA (ncRNA) transcripts 
(Derrien et al., 2012; Djebali et al., 2012). 
Until recently, most of the known non-coding RNAs fulfilled the relative generic 
function of being ‘infrastructural’ RNAs, such as rRNAs and tRNAs involved in 
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translation, spliceosomal uRNAs and small nuclear RNAs (snRNAs) involved in 
splicing and small nucleolar RNAs (snoRNAs) involved in the modification of 
rRNAs. 
Besides their structural role, some of these ncRNAs partecipate in regulatory 
processes. For examples, U1 RNA is an interactor of TFIIH and regulates RNA 
transcription (Kwek et al., 2002); small RNAs with similarity to box H/ACA sno 
RNA are components of telomerase and mutated in a genetic form of dyskeratosis 
congenital (Vulliamy et al., 2001); 7SL RNA is a component of the Signal 
Recognition Particle (SRP) that plays a key role in the delivery to the ER of proteins 
with a leader sequence (Nagai et al., 2003). 
The world of ncRNA adds new members on almost a daily basis. Several types of 
classification have been proposed based on the length of the RNA species, their 
locations on the genome and their function. Classes of non-coding transcripts can be 
divided between housekeeping ncRNAs, which are constitutively expressed, and 
regulatory ncRNAs, which are further distinguished between long and short 
according to their length (Ponting et al., 2009). Representative examples for each 
class of regulatory ncRNAs follow. 
 
 
Small Nucleolar RNAs 
Small nucleolar RNAs (snoRNAs) generally range from 60 to 300 nucleotides and 
guide the site-specific modification of nucleotides in target RNAs via short region of 
base-pairing. There are two classes of snoRNAs: the box C/D snoRNAs that guide 
the O’-ribose-methylation, and the H/ACA box which drives the pseudouridylation of 
target RNA. Initially it was thought that snoRNAs functions were restricted to 
ribosomal RNA (rRNA) modification in ribosome biogenesis, given their specific 
nucleolar localization. Now it is evident that they can target other cellular RNAs, as 
evidenced by the snoRNA involved in the aberrant splicing of the serotonin receptor 
5-HT-(2C)R gene in Prader-Willi syndrome patients (Kishore and Stamm, 2006). 
Although the snoRNA involved in ribosome biogenesis are located in the nucleolus, a 
subset of C/D snoRNAs is located into Cajal bodies (Meier, 2005). Most of them 
come from intronic regions of protein-coding genes, but apparently some snoRNAs 
are independently transcribed as evidenced by the presence of methylated guanosine 
at their 5’ end (Kiss, 2002). 
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Small Interfering RNAs and MicroRNAs 
Small interfering (siRNAs) and microRNAs (miRNAs) are 22 bps nucleotides long 
RNAs that derives from stem-loop or double-stranded RNA precursors, respectively. 
Sources of siRNAs precursors are both endogenous genomic loci and foreign nucleic 
acid introduced into the cytoplasm (Mello and Conte, 2004). Centromeres, 
transposons, repetitive sequences, and specific genomic transcripts are sources of 
endogenous siRNAs (Allen et al., 2005). 
miRNA derive from introns or exons of numerous protein-coding and non-coding 
genes (Lee et al., 2004; Rodriguez et al., 2004) as well as from retrotransposon 
sequences (Smalheiser and Torvik, 2005). miRNAs are transcribed by RNA 
Polymerase II from introns of numerous protein-coding and non-coding genes (Lee et 
al., 2004; Rodriguez et al., 2004) as primary miRNA (pri-miRNA) transcripts. The 
hairpin structure formed in these pri-miRNA transcripts are processed by RNase III 
enzyme Drosha into pre-miRNA, then exported from the nucleus and processed by 
Dicer to form the mature miRNA. The double strand mature miRNA is then 
incorporated into RNA-induced silencing complex (RISC) and acts as an adaptor for 
miRISC to specifically recognize target mRNAs. The interaction of miRISC with the 
3’ Untranslated Region (UTR) of target mRNA results into either cleavage, or 
translational inhibition of the target mRNA (Bartel, 2004). The nature of miRNA-
mRNA base pairing is thought to determine the regulatory mechanism of post-
transcriptional repression: perfect complementarity allows cleavage of the mRNA 
strand via activation of the RISC endonucleolytic complex (RNA interfering), 
whereas central mismatches promote repression of mRNA translation. 
The expression of miRNA is a process tightly regulated and has been estimated 
central in several processes including cell proliferation (Brennecke et al., 2003), left-
right patterning, cell-fate, neuronal gene expression (Klein et al., 2005), brain 
morphogenesis (Giraldez et al., 2005), muscle differentiation (Naguibneva et al., 
2006) and stem-cell division (Croce and Calin, 2005). 
miRNA have also a unequivocal role in human diseases. For example sequence 
variants in the binding site for miR-189 in the SLITRK1 mRNA have been linked to 
Tourette’s syndrome (Abelson, 2005). miRNA expression is clearly deregulated in 
cancer cells (Iorio et al., 2005). As another example of involvement in cancer, the 
proto-oncogene c-myc drives the expression of a cluster of six miRNAs on human 
chromosome 13; this cluster contains two miRNA (miR17-5p and miR-20a) that act 
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as translational downregulator of the E2F1 factor, a cell-cycle progressor (O’Donnell 
et al., 2005). Deregulation of miR17-5p and miR-20a is observed in various cancer 
cell models. 
Recent studies have shown that miRNA do not require evolutionary conservation and 
many newly discovered human RNA seem to be primate specific and drive ‘higher-
mammals’ specific fine tuning in gene regulation (Bentwich et al., 2005). 
 
 
Piwi-interacting RNAs 
Piwi-interacting RNAs (piRNAs) were first identified from mouse testis as 
component murine Piwi homolog (Miwi or Mili) proteins, a large subclass of 
Argonaute proteins found in all multicellular organisms with a highly conserved 
expression pattern in germ cells indicating an important role in development (Aravin 
et al., 2006; Girard et al., 2006; Grivna et al., 2006; Watanabe et al., 2008). These 
RNAs are 24-30 nucleotides long and are generated by a Dicer independent 
mechanism; mature piRNAs have 5’ uridine monophosphate and a 2-O-methylated 
3’end. 
PiRNAs are thought to be involved in gene silencing, specifically the silencing of 
transposons. In fact, the majority of piRNAs are antisense to transposon sequences, 
suggesting that transposons are piRNA targets (Malone and Hannon, 2009). In 
mammals it appears that the activity of piRNAs in transposon silencing is most 
important during the development of the embryo (Aravin and Bourc’his, 2008), and 
in both C. elegans and humans, piRNAs are necessary for spermatogenesis (Wang 
and Reinke, 2008). piRNAs direct the Piwi proteins to their transposon targets. A 
decrease or absence of PIWI protein expression is correlated with an increased 
expression of transposons. Transposons have a high potential to cause deleterious 
effect on their host (O’Donnell and Boeke, 2007), and, in fact, mutations in piRNA 
pathways are found to reduce fertility in Drosophila melanogaster (Brennecke et al., 
2008). However, piRNA pathway mutations in mice do not demonstrate reduced 
fertility; this may indicate redundancies to the piRNA system (Klattenhoff and 
Theurkauf, 2007). 
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Promoter-Associated Small RNAs 
Promoter-associated small RNAs (PASRs) are broadly defined as short transcripts 
transcribed within a few hundred bases of the transcription start site (TSS) of protein-
coding and noncoding RNAs. They have been described in all major eukaryotic 
lineages. A hidden repertoire of TSS-proximal transcripts first emerged from gene 
expression studies after removal of specific exosome components in plants and 
human cells (Chekanova et al., 2007; Preker et al., 2008). Small RNAs of at least 70 
nt long collinear with the 5’ end of mRNAs have been then described in almost all 
genes in physiological conditions (Guenther et al., 2007). 
At least three classes of these RNAs have been identified to date: (1) Promoter-
associated small RNAs (PASRs) are generally 20–200 nt long, capped, with 5' ends 
that coincide with the TSSs (Kapranov et al., 2007a). They have been first detected 
using genome-wide tiling arrays of human cell lines and subsequently analyzed with 
high-throughput sequencing. Their biogenesis is not well understood, although it may 
result from transcription of independent, capped, short transcripts or from cleavage of 
larger capped mRNAs (Fejes-Toth et al., 2009); (2) Transcription Start Site 
associated RNAs (TSSa-RNAs) are 20–90 nucleotide long and localized within -250 
to +50 of TSSs (Seila et al., 2008); (3) transcription initiation RNA (tiRNA) are 
predominantly 18 nts in length and found in human, mouse, chicken and 
D.melanogaster. Their highest density occurs downstream of TSSs with positional 
conservation across species (Taft et al., 2009). All three classes are strongly 
associated with highly expressed genes and with regions of RNA Polymerase II 
binding. They are weakly expressed, showing a bidirectional distribution that mirrors 
RNA Pol II (Fejes-Toth et al., 2009). 
Interestingly, several studies have indicated that short 19-21 nucleotide RNAs 
directed to promoter regions can be regulators of gene expression. In some cases gene 
silencing has been induced (Morris et al., 2004), whereas in others examples gene 
activation was surprisingly triggered (Janowski et al., 2007). Analysis of PASRs 
mimetics (20-250 nts) directed in trans against MYC and CTGF genes indicates that 
their levels correlate with decreased expression of the corresponding mRNAs (Fejes-
Toth et al., 2009). The manipulation of PASRs may thus be gene-specific and leading 
to positive or negative regulation of target gene expression (Janowski et al., 2007). 
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Long Non-Coding RNAs 
Long non-coding RNAs (lncRNAs) are RNA molecules whose length range from 200 
nucleotides to several kilobases. The GENCODE v7 catalog reports the annotation of 
14,880 human lncRNAs (Derrien et al., 2012). In contrast to small RNAs, which are 
highly conserved, lncRNAs are poorly conserved at the primary sequence level but 
there are several similarities in their mode of action. 
In contrast to most mRNAs, which ultimately localize to the cytoplasm after 
processing, most lncRNAs are localized in the nucleus at steady state. This is 
especially true for poly A- long ncRNAs that account for a large portion of the total 
transcribed sequences (Wu et al., 2008) and lncRNAs transcribed from intronic 
regions (Cheng et al., 2005). Just a small subset of lncRNAs is located in both 
nucleus and cytoplasm (Imamura et al., 2004; Kapranov et al., 2007b) while some 
lncRNAs seem to be selectively localized in cytoplasm (Louro et al., 2009). 
Although only a small number of functional lncRNAs have been characterized to 
date, they have been shown to control every level of the gene expression program 
(Wapinski and Chang, 2011), from chromatin remodeling to translation. Together 
with the large number of lncRNAs whose function is still to be uncovered, a 
comprehensive annotation of lncRNAs is missing. Indeed, the simplest classification 
of lncRNAs could be based on their loci of origin. On the basis of such denomination 
lncRNAs could be grouped into five separate categories: (1) transcripts that arise 
from the antisense strand of protein-coding genes, (2) transcripts that represent the 
introns of protein-coding genes, (3) transcripts that correspond to the promoters 
and/or 5’ untranslated or 3’ untranslated regions of protein-coding genes, (4) 
Independent transcripts that initiate within the protein-coding genes, and finally (5) 
transcripts originating from regions outside of protein-coding genes. 
Another proposed classification has been based on their ability to be “cis-acting” or 
“trans-acting” lncRNAs. 
Wang and Chang (Wang and Chang, 2011) recently suggested a classification based 
on the molecular functions that lncRNAs execute. They identified 4 archetypes of 
basic molecular mechanisms – signal, decoy, guide, and scaffold – whose analysis 
from an evolutionary perspective highlights a simple process of incremental 
modifications conferring alteration in molecular utility. 
In the first archetype lncRNAs function as signals. In fact, lncRNAs show cell type-
specific expression and respond to diverse stimuli, suggesting that their expression is 
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under considerable transcriptional control. As such, lncRNAs can serve as molecular 
signals, because transcription of individual lncRNAs occurs at a very specific time 
and place to integrate diverse stimuli. Some lncRNAs in this archetype possess 
regulatory functions, while others are merely by-products of transcription. The 
advantage of using RNA as a medium suggests that potential regulatory functions can 
be performed quickly without protein translation. For example, in mouse placenta, 
lncRNAs such as Air and Kcnq1ot1, which map to the Kcnq1 and Igf2r imprinted 
gene clusters, accumulate at promoter chromatin of silenced alleles and mediate 
repressive histone modifications in an allele-specific manner (Mohammad et al., 
2009). Interestingly, a new class of lncRNAs recently identified belongs to this 
archetypal group. Enhancer RNAs (eRNAs) are lncRNAs produced by activity-
dependent RNA Polymerase II binding of specific DNA enhancers. The level of 
eRNA expression from these enhancers positively correlates with the level of mRNA 
synthesis at nearby genes, suggesting that enhancers have a more active ‘‘promoter-
like’’ role in regulating gene expression (Kim et al., 2010; Wang et al., 2011a). 
In the second archetype lncRNAs function as decoys. In this group an lncRNA is 
transcribed and then binds and titrates away a protein target, but does not exert any 
additional functions. LncRNAs that fit into this functional archetype would 
presumably act by negatively regulating an effector, that is an RNA-binding protein 
(RBP). Recently, the lncRNA Gas5 (growth arrest-specific 5) has been identified as a 
novel mechanism by which cells can create a state of glucocorticoid resistance (Kino 
et al., 2010). Gas5 represses the glucocorticoid receptor through formation of an RNA 
motif from one of its stem-loop structures, mimicking the DNA motif equivalent to 
that of hormone response elements found in the promoter regions of glucocorticoid-
responsive genes. Therefore, Gas5 competes for binding to the DNA binding domain 
of the glucocorticoid receptor and effectively precludes its interaction with the 
chromosome. Interestingly, recent work on the tumor suppressor pseudogene 
PTENP1 has brought forth the idea that it may have biological function through 
sequestration of miRNAs to affect their regulation of expressed genes (Poliseno et al., 
2010). Specifically, the 3’ UTR of PTENP1 RNA was found to bind the same set of 
regulatory miRNA sequences that normally target the tumor-suppressor gene PTEN, 
reducing the downregulation of PTEN mRNA and allowing its translation. 
In the third archetype lncRNAs function as guides: the RNA transcript binds 
ribonucleoproteins (RNPs) to direct their localization to specific targets. lncRNAs can 
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guide changes in gene expression either in cis (on neighboring genes) or in trans 
(distantly located genes). The most studied and best understood cis mechanism of 
regulation by lncRNAs is the mammalian X inactivation center (Xic), a genetic locus 
that specifies a number of ncRNAs, including Xist (Plath et al., 2002). Xic controls 
the silencing of one of the two X chromosomes in female mammals, to achieve 
dosage compensation between the sexes. Initially the recruitment of polycomb 
repressive complex 2 (PRC2) is brought in cis by RepA RNA, a 1.6 kb ncRNA 
originating from the 5’ end of Xist (Wutz et al., 2002). RepA-mediated PRC2 
recruitment and H3K27 trimethylation of the Xist promoter result in the creation of a 
‘‘heterochromatic state’’ (Sun et al., 2006) that is required for transcriptional 
induction of Xist. Spreading of Xist is accompanied by the recruitment of polycomb 
and their associated chromatin modifications to the inactive X chromosome (Xi). 
More recently, a matrix protein, hnRNP U, was shown to be required for the 
accumulation of Xist RNA on the Xi (Hasegawa et al., 2010). Xist RNA and hnRNP 
U interact, and depletion of hnRNP U causes Xist to detach from the Xi and to 
localize diffusely in the nucleoplasm. An example of lncRNA guides acting in trans 
is lincRNA-p21, one of the direct p53 targets in response to DNA damage which is 
located upstream of CDKN1A gene. LincRNA-p21 is able to exert its effects on 
chromatin structure and transcription across multiple sites in the genome (Huarte et 
al., 2010). Ectopic expression of lincRNA-p21 induces gene expression changes and 
apoptosis, bypassing the upstream regulator p53. It remains to be determined how the 
repressive complex associated with lincRNA-p21 recognizes targeted gene loci and 
how this complex silences transcription. 
In the forth archetype lncRNAs function as scaffolds. LncRNAs can serve as central 
platforms upon which relevant molecular components are assembled. This is the most 
complex class where the lncRNA possesses different domains that bind distinct 
effector molecules. The lncRNA would bind its multiple effector partners at the same 
time and by doing so brings the effectors, which may have transcriptional activating 
or repressive activities, together in both time and space. The telomerase is a 
conserved reverse transcriptase specifically involved in maintenance of genome 
stability by adding back telomeric DNA repeats lost from chromosome ends. 
Telomerase catalytic activity requires the association of two telomerase subunits: an 
integral RNA subunit, the telomerase RNA (TERC) that provides the template for 
repeat synthesis, and a catalytic protein subunit, the TERT, as well as several species-
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specific accessory proteins. RNA domains have been identified in TERC that affect 
template usage (Lai et al., 2003; Chen and Greider, 2004) as well as TERT 
association (Ly et al., 2003). Mutations that alter the equilibrium between different 
conformational states of TERC result in disease states such as dyskeratosis congenital 
(Chen and Greider, 2004), presumably through disruptions of the RNA flexible 
scaffold structure into which are plugged modular binding sites for telomeric 
regulatory proteins. 
These archetypes are not meant to be mutually exclusive and an individual lncRNA 
may fulfill several groups. Rather, the combinatorial usage of archetypal molecular 
mechanisms has been proposed in order to illustrate how apparently complex 
functions can be constructed and developed through the evolution of molecular 
mechanisms. 
It is becoming clear that lncRNAs can have numerous molecular functions and it will 
be likely possible that newly discovered lncRNAs may serve to other functional 
paradigms. 
A major current issue is to understand how the molecular functions of these lncRNAs 
affect the organism. It is already known that lncRNAs are implicated in numerous 
developmental events (Amaral and Mattick, 2008), such as the formation of 
photoreceptors in the developing retina (Young et al., 2005) and the regulation of cell 
survival and cell cycle progression during mammary gland development (Ginger et 
al., 2006). The generation of specific knockout animal models will be a key tool to 
shed light on this issue and will likely definitively show that many lncRNAs are not 
transcriptional ‘‘noise,’’ but are instead required for normal development. 
LncRNAs are also misregulated in various human diseases, especially cancer 
(Prasanth and Spector, 2007), and even thought the mechanisms by which these 
transcripts affect tumor initiation and/or progression are currently unknown, some are 
already used as specific markers of tumors (de Kok et al., 2002). 
Considering all these information it is reasonable that lncRNAs can also allow us to 
identify new therapeutic pathways and may be themselves therapeutic targets of 
molecular medicine. Furthermore, lncRNAs represent a promising therapeutic 
strategy which can afford the upregulation of endogenous genes in a locus-specific 
manner (Wahlestedt, 2013). 
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Antisense Transcription 
The initial description of genomes organization has consisted in the separation 
between regulatory and protein-coding DNA stretches. This simple model has 
supported the “one region-one function” theory: a genome is a linear arrangement of 
functional elements interspersed with non-functional regions. Advances in 
transcriptomics technologies have shown that a genomic region can be used for 
different purposes giving rise to several different RNA molecules and that functional 
elements can co-locate in the same region of the genome. 
Given the extend of the transcriptional overlap in the same genomic region, a large 
portion of the non-coding transcripts can be located in antisense direction to protein-
coding loci (Fig. 1). 
 
Figura 1. Definition of cis-NATs. Cis- NATs are transcribed at the same genomic loci of other genes, 
but from the opposite direction and off the opposite DNA strand. Cis- NATs share at least partial 
sequence complementarity with their sense strand partner. Similar to cis-NATs, non-overlapping 
antisense transcripts (NOT) are transcribed at the same genomic loci as another gene. However, NOTs 
do not share sequence complementarity with the sense RNA due to the effects of splicing. 
 
 
It is estimated that 5,880 human transcription clusters (22% of those analyzed) form 
sense/antisense (S/AS) pairs with most antisense transcripts being ncRNA (Chen et 
al., 2004), an arrangement that exhibits considerable evolutionary conservation 
between the human and pufferfish genomes (Dahary et al., 2005). A detailed analysis 
of the mouse transcriptome indicated that 43,553 transcriptional units (72%) overlap 
with transcripts coming from opposite strand (Dahary et al., 2005). 
S/AS pairs or Natural Antisense Transcripts (NATs) appear to be involved in 
different cellular pathways, although it remains unclear whether they present any 
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special sequence or structure-related feature, as well as what their protein partners 
are. As far as we know, NATs appear to be a heterogeneous group of regulatory 
RNAs with a variety of different biological roles and specific pattern of expression 
(tissues, cells, developmental stages). 
Interestingly, a large fraction of NATs are expressed in specific regions of the brain, 
supporting the idea that they are involved in sophisticated regulatory brain functions 
and may be involved in complex neurological diseases (Qureshi et al., 2010). 
Many well-characterized regulatory ncRNAs acts in cis as receivers of other trans 
acting signals by forming secondary structures. Several examples of cis–acting RNAs 
are provided by the regulatory sequences found in the UTRs of mammalian genes that 
are known to be target of different processes: RNA editing, control of mRNA 
stability and/or translatability (Gebauer and Hentze, 2004; Kuersten and Goodwin, 
2003; Moore, 2005). Examples for trans-acting RNAs are the so-called riboswitches 
that are RNA molecules sensitive to several metabolic pathway, capable to bind to 
vitamins, lipids or small ligands and change their allosteric conformation in 
consequence of binding (Kubodera et al., 2003; Sudarsan et al., 2003). 
Most NATs are cis-encoded antisense RNA (Kumar and Carmichael, 1998; Vanhée-
Brossollet and Vaquero, 1998). By definition, cis-NATs are complementary RNA 
with an overlapping transcriptional unit (TU) at the same chromosomal locus. Trans-
NATs are complementary RNA transcribed from different chromosomal locations 
(Sioud and Røsok, 2004; Makalowska et al., 2005; Li et al., 2008). 
 
 
 
Characteristics of Cis-NATs 
Cis-Antisense RNAs are widely distributed across the genome, althought they have a 
propensity for being located 5’ and 3’ to protein coding RNAs (Core et al., 2008). 
According to their genomic anatomy cis-NAT are defined by their location relative to 
nearby protein-coding genes. The most common orientation for S/AS pairs is the tail-
to-tail or convergent orientation, where the 3’ ends of both transcripts align together. 
Divergent or head-to-head orientation and complete overlap cis-NAT are less 
frequent (Fig. 2). 
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Figure 2. Genomic arrangement of cis-NATs. From left to right, divergent or head-to-head S/AS 
pairs share a 5’ end overlap, whereas convergent or tail-to-tail cis-NAT overlap at their 3’ end. The 
two transcripts are fully overlapping when one transcript is entirely contained within the second. 
Modified from Faghihi and Wahlestedt, 2009. 
 
 
Antisense RNAs tend to undergo less splicing events and are often lower abundant 
than sense protein-coding partner. 
Expression of the antisense transcript is not always linked to the expression of the 
sense protein-coding partner, thus suggesting the usage of alternative regulatory 
elements. Knocking down antisense genes results in multiple outcomes, with the 
corresponding sense gene being either increased or decreased. 
These results indicate that antisense transcription can operate through a variety of 
different mechanisms and are a heterogeneous group of regulatory RNAs. Different 
models have been proposed for antisense–mediated regulation of sense gene. 
 
 
 
Figure 3. Transcription-related modulation a, In the collision model RNA transcription occurring in 
antisense direction halts sense transcription, thus transcription occurs in only one direction at any given 
time. b, During genomic rearrangements in hypervariable regions of B and T lymphocytes natural 
antisense transcription opens a transcriptional bubble that exposes ssDNA to AID. Modified from 
Faghihi and Wahlestedt, 2009. 
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The act of transcription itself in the antisense direction modulates the transcription of 
the sense RNA, either for transcriptional collision or genomic rearrangements. The 
first model is based on the assumption that RNA polymerase binds to the promoter of 
convergent genes on opposite strands and collides in the overlapping regions, 
blocking further transcription (Shearwin et al., 2005) (Fig. 3a). Genomic 
rearrangement occurs in lymphocyte B through a recombination process in the 
variable region of immunoglobulin genes (somatic hypermutation) and in lymphocyte 
T for T cell-receptor selection (class-switch recombination). RNA transcription from 
antisense direction creates a transcriptional bulge of 17 ± 1 melted bases in the target 
DNA, making it accessible to the activation-induced cytidine deaminase enzyme 
(AID). This is involved in somatic recombination and requires at least 5 nucleotides 
in ssDNA for optimal cytosine deamination (Sastry and Hoffman, 1995) (Fig. 3b). 
NATs may also be involved in epigenetic regulation of transcription through DNA 
methylation, chromatin modification and monoallelic expression. Antisense RNA 
molecule itself can bind to complementary DNA target locus and triggers DNA 
methylation, DNA demethylation and chromatin modification of non-imprinted 
autosomal loci. 
 
 
Figure 4. RNA-DNA interaction models. a, The newly formed AS RNA can induce directly or 
indirectly the DNA methyl tranferase (DMT) causing a repression of the sense RNA transcription. b, 
Newly formed antisense RNA transcripts can recruit histone-modifying enzymes (HMes) modulating 
chromatin architecture and epigenetic memory. Modified from Faghihi and Wahlestedt, 2009. 
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Some examples of antisense-mediated transcriptional silencing occurs at the promoter 
regions of α-globulin 2 (HBA2), p15, p21 and progesteron receptor (PR) gens by 
mean of methylation and heterochromatin formation (Morris et al., 2008; Schwartz et 
al., 2008; Tufarelli et al., 2003; Yu et al., 2008). The proposed mechanism can 
explain functionality even when abundance of antisense RNA molecules is very low 
(Fig. 4a). 
Pervasive antisense RNA transcription at promoter and termination regions gives rise 
to promoter-associated small RNAs (PASRs) and termini associated RNAs (TASRs) 
or promoter-upstream transcripts (PROMPTs). The local accumulation of those small 
RNAs along transcribed regions overlaps with active chromatin domain marks such 
as trimethylation of Lys4 of histone3 (H3K4me3) (Fig. 4b). 
Additionally some of the antisense-mediated epigenetic changes might spread to 
neighboring region not complementary to the antisense transcript causing either 
random monoallelic exclusion or including a whole cluster of genes, such as in 
genomic imprinting of the Kcnq1 locus. Finally, the expansion process occasionally 
involves the whole chromosome such as in the X chromosome inactivation in 
females. 
 
 
Figure 5. Nuclear S/AS pairing inhibiting senses RNA processing. a, Nuclear RNA pairing might 
occur locally after transcription interfering with sense RNA processing. b, RNA splicing Natural 
antisense transcript can cover acceptor or donor splice sites in the sense pre-mRNA. c, A-to-I editing 
by the ADAR enzyme induced by nuclear RNA duplex formation. Modified from Faghihi and 
Wahlestedt, 2009. 
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An alternative type of antisense-mediated gene regulation is based on the formation 
of hybrid RNA duplex in the nucleus that can be target of different enzymes. 
An antisense RNA can bind the relative sense mRNA, tuning the balance between 
different splicing forms. This is the case of the thyroid hormone recptor-α gene where 
the antisense transcript RevErbAα influences the splicing of the two isoform variants 
(Hastings et al., 1997). In a similar manner it can potentially cause alternative 
termination and polyadenylation of sense RNA (Fig. 5). 
Duplex formation between sense and antisense RNAs can modulate nuclear export. 
Nuclear retention is commonly observed for non-coding RNAs. Several cell stressors 
can mobilize antisense RNA molecules thus contributing to the nuclear shuffling of 
the protein-coding partner (Fig. 5c). In D.melanogaster antisense transcription is also 
been related to RNA editing. Duplex RNA formation in the nucleus can recruit 
ADAR (adenosine deaminase that act on the RNA) enzymes, which deaminates the 
target adenosine in inosine (Peters et al., 2003; Ohman, 2007). 
Instead cytoplasmic RNA hairpins can affect both RNA stability/translation or cover 
miRNA binding sites on the sense mRNA. 
The expression of the sense and antisense pair in the same cell can result in the 
activation of the endogenous siRNA processing machinery, which mediates 
sequence-specific knock-down of targeted genes. However, coexpression of NATs 
with their sense counterparts, together with the frequently observed concordant 
regulation of sense and antisense RNAs in many tissues and cell lines, provides 
evidences against endogenous siRNA being the sole mechanism of antisense-
mediated gene regulation. 
The overlapping RNA region might affect RNA stability by reducing mRNA decay, 
protecting the 5’ end of the sense RNA from exonucleolytic degradation by various 
RNases. Antisense transcript for inducible nitric oxide synthase (INOS) interacts with 
the AU-rich element (ARE) binding antigen R (HuR) suppressing iNOS degradation. 
On the contrary, antisense RNA of hypoxia inducible factor 1 α (HIF1A) alters the 
secondary structure and exposes the ARE element in mRNA reducing its stability 
(Uchida et al., 2004). In the case of β-site APP-cleaving enzyme 1 (BACE1), the 
expression of its antisense RNAs BACE1-AS enhances the mRNA half-life by two 
mechanisms, increase of mRNA stability and masking of miRNA-binding sites along 
its sequence (Faghihi et al., 2008). 
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In the case of PU.1 mRNA, its non-coding counterpart is a polyadenilated transcript 
which has a longer half-life than the protein-coding RNA. The cytoplasmic binding of 
the processed AS RNA to its corresponding sense RNA stalls PU.1 translation 
between initiation and elongation steps (Ebralidze et al., 2008). 
 
 
 
Characteristics of Trans-NATs 
A recent study on trans-NAT showed that these regulatory elements are much more 
abundant than previously expected. Although the authors had applied very stringent 
criteria for selecting trans-NATs, eliminating all the NATs originating from repeat 
regions and pseudogenes, they reported that at least 4.13% of transcriptional units of 
various species are trans-NATs (Li et al., 2008). 
Trans-NATs often originate from pseudogenes or repeat regions. Repetitive 
sequences in genome and pseudogenes have long been considered to be non-
functional artifacts of transposition pathways. However, an increasing number of 
reports point to the functional role for repetitive elements in post-transcriptional 
events (Peaston et al., 2004). 
Antisense transcription of pseudogenes may constitute a mechanism for controlling 
their cognate (parental) genes. Such a regulatory role has been demonstrated for 
topoisomerase I, neural nitric oxide synthase, inducible nitric oxide synthase and 
fibroblast growth factor receptor-3 pseudogenes (Zhou et al., 1992; Weil et al., 1997; 
Korneev et al., 1999, 2008). Importantly, recent reports proposed a role for a subset 
of mammalian pseudogenes in the production of endogenous siRNAs (endo-siRNA) 
through formation of double stranded RNA (Kawaji et al., 2008; Tam et al., 2008; 
Watanabe et al., 2008). 
Chimerical NATs are antisense RNAs with sequence complementary to more than 
one region of the genome (Nigumann et al., 2002; Lavorgna et al., 2004). They offer 
partial complementarity to more than one target transcript (Li et al., 2000), being 
capable of regulating many sense mRNA at the same time. 
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Repetitive Elements 
Most gene sequences are unique, found only once in the genome. In contrast, 
repetitive DNA elements are found in multiple copies, in some cases thousands of 
copies and most repetitive elements do not code for protein or RNA. Even thought 
about half of the human genome is comprised of repetitive sequences, what functions 
they serve, if any, are mainly unknown. The repeat content of the human genome is 
likely even higher, given that sequencing and assembly is less than perfect in repeat-
rich regions. Their presence and spread causes several inherited diseases, and they 
have been linked to major events in evolution. Repetitive elements differ in their 
position in the genome, sequence, sizes, number of copies, and presence or absence of 
coding regions within them. The two major classes of repetitive elements are 
interspersed elements and tandem arrays. 
Sequences that are "tandemly arrayed" are present as duplicates, either head-to-tail or 
head-to-head. So-called satellites, minisatellites, and microsatellites largely exist in 
the form of tandem arrays commonly localized at centromere and at or near 
telomeres. Because they are difficult to sequence, sequences repeated in tandem are 
underrepresented in the draft sequence of the human genome. This makes it difficult 
to estimate the copy number, but they certainly represent at least 10% of the genome. 
Interspersed repeated elements are usually present as single copies and distributed 
widely throughout the genome. The interspersed repeats alone constitute about 45% 
percent of the genome. The best-characterized interspersed repeats are the 
transposable genetic elements (TEs), also called mobile elements or "jumping genes" 
and recently, TEs have been identified as the major contributors to the origin, 
diversification, and regulation of vertebrate lcnRNAs (Kapusta et al., 2013). 
TEs may be categorized by their mobilization mechanism as either DNA transposons 
or retrotransposons. DNA transposons propagate via a cut-and-paste mechanism and 
unlike other TEs, they are found in both eukaryotes and prokaryotes. In contrast, 
retrotransposons use an RNA intermediate; are reverse transcribed; and move within 
the genome through a copy-and-paste mechanism. Retrotransposons are the most 
abundant class of TEs and they are further subdivided into two groups on the basis of 
presence or absence of Long Terminal Repeats (LTRs). The most prominent members 
of LTR-retrotransposons are endogenous retroviruses (ERVs). Essentially, such 
elements are endogenous retroviruses, which result from viral infections of germ 
cells. ERVs comprise about 8% of the human genome (Lander et al., 2001). 
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Two main families of non-LTR retrotransposons are actively mobilized. These are 
Long Interspersed Elements (LINEs), and Short Interspersed Elements (SINEs). Their 
success is evident through the fact that non-LTR retrotransposons occupy about one-
third of the human genome, making them the most populous TE group in the human 
genome (Lander et al., 2001). 
LINEs are the only currently known autonomous (providing its own enzymatic 
machinery for retrotransposition) retrotransposons that are currently mobilizing 
within the human genome. They comprise about 17% (∼500,000 copies) of the 
human genome (Lander et al., 2001). LINEs are widespread among eukaryotes, but 
are less common among unicellular ones. 
Among TEs SINEs are one of the most prolific mobile genomic elements in most of 
the higher eukaryotes, but their biology is still not thoroughly understood. SINEs 
length ranges from 100 to 600 bp (Kramerov and Vassetzky, 2005; Ohshima and 
Okada, 2005; Deragon and Zhang, 2006). The genomes can contain tens or hundreds 
of thousands of SINE copies. These copies are not identical and their sequence can 
vary by 5–35%. Altogether, these sequences constitute a SINE family. In contrast to 
all other TEs transcribed by RNA Polymerase II, SINEs are transcribed by RNA 
Polymerase III (Pol III) and contain a Pol III promoter in their sequence. SINEs 
encode no proteins and have to use LINE reverse transcriptase (RT) for their 
retrotransposition (Jurka, 1997; Kajikawa and Okada, 2002; Dewannieux et al., 
2003). SINEs are widespread among eukaryotes but not as wide as other TEs. 
Apparently, they can be found in all mammals, reptiles, fishes, and some 
invertebrates. SINEs are also common in many flowering plants. At the same time, 
D.melanogaster species lack SINEs, and SINEs are missing in most unicellular 
eukaryotes. 
The organism’s interaction with SINEs (as well as with other mobile genetic 
elements) largely resembles the host–parasite coevolution. Essentially, SINEs are 
genomic parasites and can cause damage to the host genome through insertional 
mutagenesis or unequal crossover. At the same time, SINE copies can be beneficial 
for the host as sources of promoters, enhancers, silencers, insulators, and even genes 
encoding RNAs and proteins; they can underlie alternative splicing and 
polyadenylation; finally, SINE RNAs can act as trans factors of transcription, 
translation and mRNA stability (Makalowski, 2000; Ponicsan et al., 2010; Gong and 
Maquat, 2011). 
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Nevertheless, the organism tries to suppress SINE amplification using, for example, 
APOBEC3-mediated system (Chiu et al., 2006; Hulme et al., 2007) or SINE DNA 
methylation (Rubin et al., 1994). As LINE RT is required for SINE amplification, 
LINE repression also protects the genome from SINE expansion. LINEs can be 
repressed through RNA interference or the APOBEC3 system, and the repression can 
be fixed by DNA methylation. At the extremes, too aggressive SINEs (or LINEs) can 
destroy their host organism and are eliminated by selection; on the other hand, there 
are many examples of SINE family death (cessation of amplification). More 
commonly, ups and downs in the activity of particular SINEs or LINEs are observed. 
 
 
 
Structure and Classification of SINEs 
Most SINEs consist of two or more modules: 5’ terminal ‘head,’ ‘body’ and 3’ 
terminal ‘tail.’ 
The head of all SINE families known to date demonstrate a clear similarity with one 
of the three types of RNA synthesized by Pol III: tRNA, 7SL RNA, or 5S rRNA (Fig. 
6). 
 
Figure 6. SINE structure examples. a, Ther-1 is a tRNA-derived CORE SINE of stringent 
recognition group. b, Ped-1, 5S rRNA-derived SINE of stringent recognition group with bipartite 
LINE region. c, B1, 7SL RNA-derived quasi-dimeric SINE of relaxed recognition group. d, CAN, 
tRNA-derived SINE of relaxed recognition group with a variable polypyrimidine region. e, MEG-RS, 
simple 5S rRNA-derived SINE of relaxed recognition group. f, MEN, dimeric tRNA/7SL RNA 
(heterodimeric) SINE of relaxed recognition group. Modified from Kramerov and Vassetzky, 2011. 
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The SINE head similarity with one of the cellular RNAs suggests its origin from this 
RNA. SINEs originating from tRNAs are particularly abundant. A particular tRNA 
species of origin can be confidently identified for many SINE families, although 
nucleotide substitutions in SINE evolution make it impossible in other ones. To date, 
7SL RNA-derived SINEs have been identified only in rodents (Krayev et al., 1980; 
Veniaminova et al., 2007), primates (Deininger et al., 1981; Zietkiewicz et al., 1998) 
and tree shrews (Nishihara et al., 2002; Vassetzky et al., 2003). The 7SL RNA (B300 
nt) is found in all eukaryotes as the RNA component of the Signal Recognition 
Particle (SRP), the ribonucleoprotein that targets secreted proteins to the endoplasmic 
reticulum. The number of SINE families originating from 5S rRNA is also not high; 
they have been found in some fishes (Kapitonov and Jurka, 2003; Nishihara et al., 
2006) and in a few mammals: fruit bats (Gogolevsky et al., 2009) and springhare 
(Gogolevsky et al., 2008). The genes of all these RNAs (as well as the corresponding 
SINEs) have an internal Pol III promoter. The promoter in tRNA and 7SL RNA genes 
consists of two boxes (A and B) of about 11 nt spaced by 30–35 nt, while the 5S 
rRNA genes have three such boxes: A, IE and C (Schramm and Hernandez, 2002). 
The presence of the promoter within the transcribed sequence is critical for SINE 
amplification, as the promoter is preserved in new SINE copies. 
The body of most SINE families (67%) consists of a central sequence of unknown 
origin. The central sequence is specific for each SINE family; however, it can contain 
domains common for distant families. Currently, four such domains are known: 
CORE domain in vertebrates (Gilbert and Labuda, 1999), V-domain in fishes 
(Ogiwara et al., 2002), Deu-domain in deuterostomes (Nishihara et al., 2006) and 
Ceph-domain in cephalopods (Akasaki et al., 2010). A substantial fraction of SINEs 
(20%) has a 30–100 bp region of similarity with the 3’ terminal sequence of LINE, 
whose RT is involved in SINE amplification (Ohshima and Okada, 2005). The LINE-
derived regions of SINEs are required for the recognition of their RNA by the RT of 
some LINEs, while RTs of other LINEs require no specific recognition sequence. 
Accordingly, SINEs are divided into the stringent and relaxed recognition groups. 
The tail is a sequence of variable length consisting of simple (often degenerate) 
repeats. All SINEs have the 3’ terminal tail composed of repeated mono-, di-, tri-, 
tetra- or pentanucleotides. The tail of many SINEs is a poly(A) or irregular A-rich 
sequence (A-tail), the amplification of all such SINEs in mammals depends on the RT 
of LINE1 family (L1). In some SINEs, the end of A-rich tails can contain the signals 
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of transcription termination and polyadenylation responsible for the synthesis of 
poly(A) at the 3’ end of SINE RNA (Borodulina and Kramerov, 2008). 
At the same time, not all SINEs have body (in particular, all known 7SL RNA-
derived SINEs): 6% of SINE families consist of the head and tail only. Such elements 
resembling pseudogenes of cellular RNAs are called simple SINEs and can be 
distinguished from pseudogenes by specific nucleotide substitutions, which indicate 
their immediate origin from a SINE copy with such substitutions rather than from an 
RNA gene (Gogolevsky et al., 2009). 
On the other hand, the structure of SINEs can be more complex. Two or more SINEs 
can combine into a dimeric (or a more complex) structure, which is further amplified 
as a dimer. Representatives of the same or different SINE families can combine. One 
of the first discovered SINEs, Alu in primates, consists of two similar parts derived 
from 7SL RNA (Deininger et al., 1981; Ullu and Tschudi, 1984). There are dimeric 
and trimeric SINEs derived from tRNAs (Schmitz and Zischler, 2003; Churakov et 
al., 2005). On the other part, complex elements composed of different SINE families 
or even types have been described. There are many such SINEs combining simple 
7SL RNA- and tRNA-derived elements (Fig. 6f); most of them were described in 
rodents (Serdobova and Kramerov, 1998; Veniaminova et al., 2007; Churakov et al., 
2010), but they also exist in primates (Daniels and Deininger, 1983). Hybrid 5S 
rRNA/tRNA SINEs have been described (Nishihara et al., 2006; Gogolevsky et al., 
2009), while no SINEs combining 7SL RNA- and 5S rRNA-derived elements are 
known yet. 
 
 
Origin and Evolution of SINEs 
The origin of a new SINE family is a multistage process. SINE amplification relies on 
at least two processes, transcription and reverse transcription/integration, and a SINE 
genomic copy should be efficiently transcribed, while its RNA should be efficiently 
reverse transcribed within the period when active LINE RT is available. 
SINEs originate from pseudogenes of tRNAs, 7SL RNA or 5S rRNA but the majority 
of 7SL RNA pseudogenes are not transcribed, as the transcription of 7SL RNA genes 
depend on the regulatory elements upstream of the gene in addition to the internal 
promoter (Ullu and Weiner, 1985). Accordingly, a 7SL RNA pseudogene 
transformation into a SINE requires modifications that allow its transcription 
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irrespective of the flanking sequences. It is possible that the deletion of the central 
region and/or smaller mutations in the 7SL RNA pseudogene in the genome of the 
common ancestor of primates and rodents have eventually led to the emergence 
human Alus and mouse SINE B1s. Apparently, most tRNA pseudogenes with intact 
internal promoter can be transcribed, and their conversion into SINEs requires no 
such radical modifications. Thus, SINEs emerged from tRNAs many times during 
evolution but, probably, only once from 7SL RNA. 
Reverse transcription of foreign molecules by LINE RT is an extremely rare event 
compared with the reverse transcription of LINE RNA. Currently, we know two 
systems protecting LINE RTs from processing foreign templates: sequence 
recognition of the RNA encoding the enzyme and cis-preference, when the RNA 
molecule used for RT translation is used by the translated enzyme as the template for 
reverse transcription (Esnault et al., 2000; Wei et al., 2001; Kajikawa and Okada, 
2002). Overcoming this protection is an essential step in SINE formation. In the first 
case, it is realized by the acquisition of the fragment(s) recognized by the RT. The 
mechanism of cis-preference violation remains unclear; the SINE RNA interaction 
with the factors of the RT complex can be proposed. For instance, B1 and Alu (as 
well as 7SL) RNAs form a complex with SRP proteins SRP9/14 (Weichenrieder et 
al., 2000), which can bind to polyribosomes. This way B1 and Alu transcripts can be 
presented to the synthesized L1 RT as the template for reverse transcription. A similar 
mechanism can be proposed for SINEs derived from tRNAs or 5S rRNA, components 
of the ribosomal complex. The cis-preference violation can be mediated by poly(A)-
binding protein, which can bind proteins of the translational machinery (Roy-Engel et 
al., 2002); in this case, the acquisition of an A-tail should be an essential step in the 
evolution of SINEs mobilized by an RT with cis-preference. In some SINEs (for 
example, rodent B2), a polyadenylation signal at the 3’ end provides for the A-tail 
synthesis (Borodulina and Kramerov, 2008). 
Former evidences suggest that SINE RNA should not be involved in the gene 
processes of the cellular RNA from which it originates. This assumes accumulations 
of changes from the original structure. For instance, transcripts of simple tRNA-
derived SINEs cannot form the clover leaf structure, and their nucleotides are not 
modified as in tRNAs (Rozhdestvensky et al., 2007; Sun et al., 2007). As a result of 
such changes, SINE transcripts lose the capacity to bind to at least some protein 
factors of tRNA processing or transport. This excludes SINE transcripts from tRNA 
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biochemical pathways and opens up a way for efficient retroposition. A similar 
pattern can be expected for the conversion of 7SL RNA and 5S rRNA pseudogenes 
into SINEs. For instance, B1 and Alu transcripts largely lose the similarity with the 
7SL RNA secondary structure, although the structure of two domains is preserved 
(Labuda and Zietkiewicz, 1994). 
In addition to transcription and reverse transcription, SINE replication involves other 
yet poorly known processes such as SINE RNA degradation or nuclear export 
(Kramerov and Vassetzky, 2005). The transport of SINE RNA is likely mediated by 
the interaction of its domains with cellular factors. For instance, Alu RNA transport is 
likely mediated by SRP9 and SRP14 (He et al., 1994). However, the absence of 
universal SINE structure responsible for its transport suggests different pathways of 
their RNA transport and, accordingly, different pathways for the acquisition of this 
function. 
 
Figure 7. Mechanisms of SINE variation during their life cycle. Modified from Kramerov and 
Vassetzky, 2011. 
 
 
The life cycle of SINEs includes DNA and RNA stages (Fig. 7). Little is known 
about the factors that determine their duration, but it can vary substantially. Clearly, a 
decline in LINE activity makes impossible further SINE amplification. Thus, 
correlation in activity is observed for many SINE/LINE partners. 
In contrast to other mobile genetic elements, SINEs emerged in evolution many 
times. For instance, at least 23 primary SINE families independently appeared in the 
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evolution of placental mammals (currently, 51 mammalian SINE families have been 
described). This amazing property results, on the one hand, from their simple modular 
structure and the availability of the source modules (for example, tRNA or 3’ end of 
LINE) in the cell. Moreover, high variation in SINE structures suggests that there are 
no stringent requirements for their nucleotide sequences excluding several short 
conserved regions. On the other hand, the emergence and replication of SINEs 
depend on LINE RT, which is not very secure from processing foreign sequences. 
Interestingly, some modules and RTs are particularly favorable for SINE emergence. 
According to the number of their genomic copies, dimerization is usually a 
progressive evolutionary event; however, dimeric SINEs are not necessarily more 
successful than the monomeric counterparts. 
Non-mammals SINEs are unrelated to SRP RNA and believed to be derived from 
tRNA species. However, SINEs from mammals belong to either SRP- or tRNA-
derived superfamilies. Rodents genomes contain both SRP RNAs (B1 elements) and 
tRNA superfamily (B2) SINEs, with SINEB1 basically resembling the left human 
Alu monomer. Prosimiam species have both SINEs, B1 and B2, and full-length 
dimeric Alus. This intermediate composition suggests a transition between rodents 
and human. Sequence database analysis and hybridization experiment excluded the 
presence of tRNA SINEs in human genome. The reason why Alus flourished in 
higher primate genome while tRNA SINEs are undetectable is still unknown. It can 
be either that Alus may have established a state of complete neutrality with the human 
host or more probably they have compensated their hosts with selective advantages. 
Several experimental evidences suggest that Alus may serve a variety of functions. 
The human Alu is the most extensively studied SINE and it exemplifies most features 
of this unusual class of sequences. 
There are at least 1 billion Alus per haploid genome (Schmid, 1996). Individual Alus 
share a common consensus sequence of 283 bps which is typically followed by a 
3’A-rich region resembling poly(A) tail (Fig. 8). The Alu consensus sequence is a 
divergent tandem dimer in which the two monomers are separated by a short A-rich 
region that flanked the ancestral monomer. Except for 30 nucleotide insertion in the 
right monomer, Alu monomers are homologous to SRP RNA, also known as 7SL 
RNA. Most Alus are flanked by short direct repeats which represent the duplicated 
insertion sites. 
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Figure 8. Transcription of Alu elements by Pol II and Pol III. a, Free Alu RNA. This hypothetical 
Alu element, shown in green, is transcribed by its internal Pol III promoter elements (Box A and Box 
B), which are helped by an upstream Pol III enhancer (or upstream promoter elements) for efficient 
transcription. A Pol III terminator (TTTT-3’) is depicted downstream of the Alu element. Both Pol III 
enhancer and terminator are provided by the locus of integration of the Alu element. The secondary 
structure of the resulting Alu RNA was drawn based on the secondary structure determined by Sinnett 
et al., 1991 and adapted to the sequence of the Alu element of intron 4 of the a-Fetoprotein gene, 
which was shown to bind the SRP9/14 proteins. Underlined letters indicate the binding sites of 
SRP9/14 by analogy to SRP RNA. b, Embedded Alu RNA. This hypothetical Alu element, shown in 
green, is located inside of a protein-coding gene. It might be inserted into an intron, a UTR, and 
exceptionally into a coding region. This Alu element is then transcribed by Pol II, embedded inside a 
larger transcription unit. Depending on the sequence environment, as well as on its own sequence, the 
embedded Alu RNA might adopt a typical Alu fold. Modified from Häsler et al., 2007. 
 
 
Alu elements inherited the two highly conserved sequences A and B boxes from the 
7SL RNA promoter gene. However these elements are not sufficient to drive the 
transcription in vivo and Alus depend on flanking sequences for their expression. 
RNA Pol III-dependent transcripts of this class are referred to as “free” Alus. 
Alus transcribed in the context of larger transcriptional units of both protein coding 
and non-coding RNAs are called “embedded” Alus. Katerina Straub and collegues 
screened the human transcriptome to identify Alu elements contained in the 
transcribed UTRs of human cDNA library. They identified 299 Alus embedded in the 
5’ UTRs of 244 transcripts and 2142 Alus embedded in the 3’ UTRs of 1548 
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transcripts (http://cms.unige.ch/sciences/biologie/bicel/Strub/researchAlu.html). For 
Alu RNAs embedded in 5’ UTRs of specific mRNAs, a role in inhibiting translation 
has been proved. BRCA1 presents a transcript isoform specifically expressed in 
cancer tissue that contains an Alu sequence in its 5’ UTR forming a stable secondary 
structure and causing a translational defect (Sobczak and Krzyzosiak, 2002). 
Similarly, an antisense Alu element in the 5’ UTR of the zinc finger protein ZNF177 
(Landry et al., 2001), in the growth hormone receptor (Goodyer et al., 2001) and in 
the contactin mRNA isoform (Rome et al., 2006) decreased the translation efficiency 
of relative mRNAs. Concerning Alu elements in the 3’ UTR, it has been proposed 
that inverted Alus could generate adenine and uracile rich element called AREs, as 
for the LDL receptor transcript (Wilson et al., 1998). 
A function for Alu elements embedded in mRNA has also been identified. RNA 
editing is a very well characterized post-transcriptional RNA modification which 
consists in conversion of adenosine to inosine via the deaminase activity of a class of 
enzymes called ADARs (Adenosine Deaminase acting on RNA). Alus account for the 
90% of editing events in nuclear RNA (Nishikura, 2006). ADAR enzymes 
preferentially edit adenosine present in double stranded RNA molecules and have no 
precise sequence specificity. Adenosine editing within an Alu sequence is favored 
when two Alus are present at a short distance in opposite orientation. This gives rise 
to intramolecular base pairing events as seen for NFkB1 and Cyclin M3 mRNAs 
editing (Kawahara and Nishikura, 2006). Furthermore, dsRNA formation has been 
related to nuclear retention and silencing of long non polyadenilated nuclear RNA 
(Chen et al., 2008). 
 
 
Mouse SINE elements 
Rodents genomes contain both SRP RNAs (B1) and tRNA superfamily (B2) SINEs 
with SINEB1 basically resembling the left human Alu monomer. 
SINEs are the only transposable elements transcribed by RNA Polymerase III (Pol 
III). Cellular RNA Pol III can transcribe SINEs due to the presence of an internal 
promoter in their 5′ region, which is composed of A and B boxes spaced 30–40 
nucleotides apart. SINE B1 family in mice originated from 7SL RNA, a component 
of SRP, involved in translation of secreted proteins in all eukaryotes. All these SINE 
families include sequences corresponding to the terminal regions of 7SL RNA with 
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the central 144–182 nucleotides deleted. In contrast to human Alu, murine or rat B1 
(140 bp) is a monomer. However, it has an internal 29-bp duplication, which 
prompted Labuda et al. to consider B1 as a quasi-dimer (Labuda et al., 1991). 
Mouse B2 RNA is encoded by short interspersed elements dispersed throughout the 
mouse genome with ∼350,000 copies per cell. SINEB2s are transcribed by RNA Pol 
III to produce B2 RNAs that are ∼180 nucleotides in length. The promoter elements 
(e.g., the A box and B box) that drive transcription are downstream from the 
transcription start site and therefore contained within the early transcribed region of 
SINEB2s. The 70 nucleotides at the 5′ end of B2 RNAs are evolutionary related to 
tRNAs, and the very 3′ end of B2 RNAs contain an A-rich sequence conserved 
among all SINEs (Kramerov and Vassetzky, 2005). 
Examples of functional roles for mouse SINEB2 elements follow. 
 
 
 
SINEB2 as Chromatin Boundary Element 
During the development of the pituitary gland, in specific cells, the murine growth 
hormone (GH) becomes transcriptionally active. At embryonic stage 17.5 the 
promoter passes from a state in which H3 is trimethylated at K9 site (which is a mark 
for condensed heterochromatin) to a state in which H3 is dimethylated. The 
chromatin boundary where this transition starts has been localized to a region 10–14 
Kb upstream of the GH transcription start site. Intriguingly, this region contained a 
SINEB2 element. 
To test the hypothesis of the boundary element, a 1.1 Kb region containing the 
SINEB2 module has been tested for its enhancer blocking activity when placed 
between enhancer and the core promoter of a reporter gene and it resulted that the 
SINEB2 is necessary to block reporter gene expression. Strand specific PCR 
experiments showed that ongoing transcription through the RNA Pol III promoter (in 
sense direction) and through the RNA Pol II promoter (antisense direction) is 
important for enhancer blocking activity. These results suggest that a mouse SINEB2 
serves as a boundary element and its bidirectional transcription causes a 
developmentally relevant change in chromatin structure (from heterochromatin to 
euchromatin), which establishes a permissive environment that allows transcription of 
the GH gene (Lunyak et al., 2007) (Fig. 9). 
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Interestingly, in human cells over 9,000 Alus are found within 1 Kb upstream of 
transcription initiation sites, raising the possibility that some Alu SINEs might also 
affect mRNA transcription by serving as boundary elements (Dagan et al., 2004). 
tRNA genes have been found to serve as boundary elements in yeast, but the 
mechanism of function also appears to be somewhat different from that of the GH 
SINEB2 (Lunyak, 2008). Although ongoing RNA Pol III transcription of tRNA genes 
is required for boundary element function in yeast, there is no evidence of antisense 
RNA Pol II transcription through the tRNA genes. 
 
Figure 9. A B2 SINE serves as a boundary element to regulate transcription during pituitary 
development in mouse cells. Bidirectional transcription of a B2SINE upstream of the growth hormone 
locus facilitates a change in chromatin structure from a repressive heterochromatic state to a 
permissive euchromatic state. Modified from Ponicsan et al., 2010. 
 
 
 
SINEB2 and Alus as Trans-Regulators of mRNA Transcription 
SINEB2 and Alu RNAs may function as repressors of mRNA transcription during 
heat shock. As cells respond to heat shock, transcription of some genes is upregulated 
(e.g., hsp70), while transcription of others is repressed (e.g., β-actin, and hexokinase 
II) (Allen et al., 2004; Mariner et al., 2008). When Alu or SINEB2 RNAs are 
silenced, transcriptional repression at several genes upon heat shock is abrogated, 
indicating that SINEB2 and Alu RNAs act as inhibitor of transcription. 
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In an in vitro transcription system, Alu RNA and SINEB2 RNAs were potent 
repressors of RNA Pol II. Interestingly, physical binding of B2 RNA and Alu RNA to 
core Pol II has been demonstrated. Consistent with this finding, ChIP assays have 
proved that in heat shocked mouse or human cells, SINEB2 RNA or Alu RNA 
colocalize with Pol II at the promoters of transcriptionally repressed genes. These 
observations led to the model where Alu RNA and SINEB2 RNA are upregulated 
upon heat shock, bind RNA Pol II to enter complexes at promoters, and finally block 
transcription (Fig. 10). 
 
Figure 10. SINE RNAs control the heat shock response in mouse and human cells. a, Pol III 
transcribed SINE RNAs increase upon heat shock. b, During heat shock, mouse B2 RNA or human 
Alu RNA enters complexes at the promoters of repressed genes. TFIIF facilitates dissociation of B1 
RNA from Pol II. c, Heat shock activated genes are resistant to repression by B2 RNA and Alu RNA. 
Modified from Ponicsan et al., 2010. 
 
 
Deletion studies with SINEB2 RNA gave the first hints that these ncRNA share 
distinct functional domains. Nucleotides 81–130 of B2 RNA were fully functional for 
binding Pol II and repressing transcription in vitro; however, further truncation to 99–
130 yielded an RNA domain capable of binding Pol II, but lacking the ability to 
repress transcription. Similarly, deletion analysis of Alu RNA demonstrated that it 
had two separable ‘Pol II binding’ domains and two different ‘transcriptional 
repression’ domains (Mariner et al., 2008). 
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A series of in vitro studies were performed to determine the molecular mechanism by 
which Alu RNA and B2 RNA repress transcription. Given that these ncRNAs co-
occupy promoters with Pol II, they likely repress transcription after complexes bind 
to DNA but before initiation. They do so by preventing RNA Pol II from properly 
engaging the DNA after assembling into complexes with promoter-associated 
transcriptional factors (Fig. 10). B1 and B2 RNAs bind Pol II competitively and with 
similarly high affinity, which raised the intriguing question of whether B1 RNA could 
block B2 RNA from binding Pol II and repressing transcription. This possibility was 
investigated using an in vitro transcription system, and surprisingly, B2 RNA was 
found to repress transcription when B1 RNA had been pre-bound to Pol II (Wagner et 
al., 2009). Further experiments elucidated that TFIIF facilitates the dissociation of B1 
RNA from Pol. II (Fig. 10). Moreover, fusing a transcriptional repression domain 
from Alu RNA onto B1 RNA created a chimerical ncRNA that remained stably 
bound to Pol II in the presence of TFIIF, showing that repression domains make RNA 
Pol II–ncRNA complexes resistant to the destabilizing effects of TFIIF. 
 
 
Figure 11. Model for the secondary structure of B2 RNA. Nucleotides 1–155 of B2 RNA are 
shown. Nucleotides 156–178, which constitute an A-rich single-stranded 39 tail, are not shown in the 
model. Symbols in parentheses indicate positions cleaved only weakly. Predominant features in the 
secondary structure are labeled as: stems 1–6 (S1–S6), bulges 1 and 2 (B1 and B2), loops 3–6 (L3–L6), 
and single-stranded regions 1–3 (SS1–SS3). Modified from Espinoza et al., 2007. 
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With the goal of understanding which regions of B2 RNA are important for high-
affinity binding to RNA Polymerase II and repression of transcription, Espinoza et al. 
performed a structural and deletion analysis of a 178 nucleotide B2 RNA. (Espinoza 
et al., 2007). Deletion studies revealed that a 51-nucleotide region (from 81 to 131) of 
B2 RNA is sufficient for high-affinity binding to RNA Polymerase II, association 
with preinitiation complexes, and repression of transcription in vitro, the latter of 
which involves a large predominately single-stranded region within the RNA. In 
addition, this piece of B2 RNA blocked the polymerase from properly associating 
with template DNA during the assembly of elongation complexes. Further deletion 
revealed that a 33-nucleotide piece of B2 RNA (from 99 to 131) binds RNA 
Polymerase II, associates with preinitiation complexes, but cannot repress 
transcription. These results support a model in which RNA Polymerase II contains a 
high-affinity ncRNA docking site to which a distinct region of B2 RNA binds, 
thereby allowing another region of the RNA to repress transcription. Moreover, the 
mechanism of transcriptional repression by B2 RNA likely involves disrupting 
critical contacts between RNA Polymerase II and the promoter DNA (Fig. 11). 
 
 
 
SINEB2 and Alu RNAs as Trans-Regulators of Translation 
Cell stress dramatically increases the abundance of human full length Alu RNAs (fl 
Alu RNAs) and other mammalian SINE RNAs (Fornace and Mitchell, 1986; Liu et 
al., 1995). For example, heat shock causes a nearly 100-fold increase in mouse B1 
RNA making this sparse transcript abundant (Fornace and Mitchell, 1986). Mouse B2 
and rabbit C RNAs show similar increases, indicating that the heat shock response is 
conserved by the SRP RNA and tRNA SINE superfamilies. In addition to heat shock, 
other classic cell stress treatments increase full length Alu RNAs (flAlu RNA). Cell 
stress does not change the lifetime of flAlu RNA but probably increases Alu 
transcription (Liu et al., 1995). Viral infection or administering cycloheximide to cells 
also significantly increases the abundance of SINE RNA (Singh et al., 1985; Jang and 
Latchman, 1992; Jang et al., 1992; Panning and Smiley, 1993, 1995). The induction 
of Alu RNA by either cycloheximide or heat shock occurs <20 min after subjecting 
cells to these stresses (Liu et al., 1995). 
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The rapidity of these responses suggests that they arise from the modification of 
existing factors and do not involve either DNA demethylation or de novo synthesis. 
Do these increases in SINE RNA merely reflect an aberrant breakdown in regulation 
or are they a controlled response? Schmid and colleagues have shown that after viral 
infection, along with a global block in protein synthesis, the cytoplasmic 
concentration of flAlu RNAs dramatically increases. The halt of translation initiation 
that we observe after exposure to viral-stress is usually due to a change in the activity 
of PKR (double-stranded RNA activated kinase). The PKR is an intracellular protein 
kinase whose function is to sense cell stresses. Upon exposure to double stranded 
viral RNA PKR increases its autophosphorylation activity and hyperphosporylate the 
α subunit of eiF2 complex. eIF2 is responsible for the transport of the metionil-tRNA 
at the site of translation initiation. Phosphorylation of eIF2α on Ser-51 inhibits the 
formation of the ternary complex with the met-tRNA and impairs general translation 
levels. Small highly structured RNAs (like Alu RNAs) sequester PKR as bound 
monomers and inhibit its autophosphorylation, thereby potentially increasing protein 
synthesis. Since flAlu RNAs increase protein synthesis after viral infection, it has 
been proposed that this is mediated by PKR inhibition. However, translation 
stimulation is still present in knock-out cells (Rubin et al., 2002). 
The absence of Alu RNAs in most mammals and tRNA SINEs in humans indicates 
that their sequence per se is not essential for function but their secondary structure is 
important. PKR binding primarily requires only a minimum number of base pairs 
within an RNA secondary structure so that several unrelated RNA sequences can 
functionally be Alu-substitutes as PKR inhibitors (Bhat and Thimmappaya, 1983; 
Clemens, 1987). As a classic example, when cells are infected and PKR activation 
blocks protein synthesis, the adenoviral VAI RNA gene inhibits virally induced PKR 
activation, restoring viral protein synthesis. Both protein synthesis and viral 
infectivity are impaired for VAI mutants. As another example of PKR binding 
element, the gene for an entirely unrelated RNA, EBER1, rescues both infectivity and 
protein synthesis for VAI mutants (Bhat and Thimmappaya, 1983). 
According to this experiment, the cell stress-induced transcripts from the tRNA SINE 
superfamily could serve the same PKR regulatory role as Alu RNA. Yet a minimal 
RNA secondary structure alone cannot be sufficient to inhibit PKR in vivo. 
Otherwise, cellular RNAs, e.g. rRNA, would present an extraordinary number of 
PKR binding sites. Presumably, rRNA and other functional RNAs are unavailable for 
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PKR binding because of their subcellular location or organization into 
ribonucleoprotein (RNP) structures. 
Similarly, short-lived flAlu RNA (Chu et al., 1995) could be rapidly reduced to basal 
levels when they are no longer required for PKR inhibition. As otherwise functionless 
RNAs, the RNP structure and subcellular location of SINE RNAs could promote their 
PKR accessibility. In support of the notion that Alu RNPs are accessible for PKR 
binding, the only other proteins known to form Alu RNPs are two small SRP 9/14 
proteins and La, which transiently binds to the 3′ ends of nascent RNA Pol III 
transcripts. 
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Parkinson’s Disease 
Parkinson’s Disease (PD) is the second most common progressive neurodegenerative 
disorder following Alzheimer’s Disease (AD) and affects 1-2% of all individuals 
above the age of 65. The main pathological hallmark of PD is the progressive loss of 
neuromelanin-containing dopaminergic neurons in the Substantia Nigra pars 
compacta (SNc) of the ventral midbrain and the presence of eosinophilic 
intraneuronal inclusions, called Lewy bodies (LBs), composed of specific 
cytoplasmic proteins like alpha-synuclein, parkin, synphilin, ubiquitin, and oxidized 
neurofilaments (Goldman et al., 1983). This cell loss entails severe dopamine 
depletion in the striatum therefore causing the motor symptoms associated with PD, 
especially bradykinesia, tremor at rest, rigidity, and loss of postural control (Ehringer 
and Hornykiewicz, 1960; Bernheimer et al., 1973). 
While the precise pathological mechanisms remain unclear, the identification of 
several genes associated with rare, heritable forms of PD have highlighted potential 
pathogenic causes, such as mitochondrial dysfunction, oxidative and nitrosative stress 
and aberrant protein degradation (Table 1). 
 
Table 1. List of PD-associated loci. 
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About 5-10% of all cases of PD are familial. Two autosomal dominant genes, (α-
synuclein and LRRK2) and three autosomal recessive genes (parkin, DJ-1 and 
PINK1) have been repetitively found mutated in inherited PD ( itada et al., 1  8  
Bonifati et al., 2002  Pais n-Ru  z et al., 2004; Valente et al., 2004; Zimprich et al., 
2004). In brief, α-synuclein was the first gene in which a mutation was identified to 
cause an autosomal dominant form of Parkinsonism (Polymeropoulos et al., 1997). 
Furthermore, it was found to be the principal constituent of Lewy bodies (Spillantini 
et al., 1997). Its function is currently not known although it seems to be involved in 
fatty acid metabolism and synaptic transmission (Sharon et al., 2003). 
LRRK2, whose function is also unknown, is a complex kinase for which it has been 
proposed that a simple gain of function could lead to toxicity (Greggio et al., 2006). 
Parkin or PARK2 is an E3 ubiquitin ligase that has been shown to ubiquitinate 
substrates and to trigger proteasome-dependent degradation or autophagy. PTEN-
induced putative kinase 1 (PINK1) or PARK6 is a mitochondrial protein kinase 
whose activity is required for Parkin-dependent mitophagy, a process that has been 
linked to neurodegeneration. In fact, PINK1 and Parkin act jointly in mitochondrial 
quality control by sensing mitochondrial dysfunction on the outer mitochondrial 
membrane and coupling it with a program of organelle degradation (Narendra et al., 
2008). 
DJ-1 or PARK7 is an atypical peroxidase with neuroprotective activity which affects 
sensitivity to oxidative stress. 
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Ubiquitin Carboxy Terminal Hydrolase L1 or PARK5 
Ubiquitin Carboxy Terminal Hydrolase L1 (Uchl1) is an abundant neuronal enzyme 
representing 1-5% of total brain protein (Wilkinson et al., 1989). It possesses a well 
characterized de-ubiquitinating activity that catalyzes the hydrolysis of carboxyl-
terminal esters and amides of ubiquitin to generate free monomeric ubiquitin (Larsen 
et al., 1996). Furthemore, Uchl1 associates with monoubiquitin and elevates the half-
life of monoubiquitin in neurons, probably by preventing its degradation in 
lysosomes. 
Interestingly, a natural Uchl1-null mutant is the Gad mouse (Gracile axonal 
dystrophy), a mouse model of a recessively transmitted neurodegenerative disease 
characterized by progressive axonal degeneration. Loss of functional Uchl1 leads to a 
decrease of free ubiquitin (Ub) and subsequent inadequate ubiquitinilation of 
proteins. A decreased Ub-dependent degradation is clearly upstream the accumulation 
of nondegradated Ub-proteins observed within the spheroid bodies in Gad mice 
(Castegna et al., 2004). 
General involvement of UCHL1 in neurodegeneration has been assessed for 
Spinocerebellar ataxia (Fernandez-Funez et al., 2000) and Hungtinton’s disease (Nazé 
et al., 2002), while its role in the pathogenesis of PD is still debated. A missense 
mutation in the UCHL1 gene leading to I93M substitution at the protein level has 
been reported in two affected siblings in a German family with an autosomal 
inherited form of PD. However, the existence of an unaffected carrier of the I93M 
mutation has questioned the link between I93M mutation and PD (Leroy et al., 1998). 
Intriguingly, I93M Uchl1 transgenic mice exhibit a clear nigrostiatal degeneration 
and progressive dopaminergic cell loss (Setsuie and Wada, 2007). Moreover, I93M 
UCHL1 shows decreased solubility and display aberrant interaction with several 
cellular proteins, including tubulin whose polimerization is severely unbalanced in 
presence of mutant I93M or carbonyl-modified UCHL1 (an oxidized form of UCHL1 
often found in PD post-mortem brains) (Kabuta et al., 2008). 
In search for additional I93M mutants, a previously unrecognized polymorphism in 
the Uchl1 gene (S18Y) was discovered and subsequently found to be linked to a 
decreased susceptibility to PD (Levecque et al., 2001). Protection of S18Y allele is 
dependent on the dosage, meaning that homozygotes have significantly lower risk 
than heterozygotes. The protection exerted by S18Y is not simply linked to UCHL1 
hydrolytic activity because S18Y variant showed similar hydrolase properties as the 
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wild type. This fact suggested the existence of a distinct enzymatic activity that 
confers a gain-of-toxic-function for I93M mutant and protective properties to S18Y 
variant. This second activity was identified in the 2002 by the group of Peter 
Lansbury in a novel dimerization-dependent ubiquitin-ligase activity. UCHL1 was 
reported to form K63 polyubiquitin chain in vitro, using α-synuclein as a model 
substrate. While I93M and wt UCHL1 increased the α-synuclein levels in transfected 
cells inhibiting its degradation, S18Y did not (Liu et al., 2002). 
Uchl1 ligase activity was found to be diminished for S18Y variant, which had indeed 
a dominant negative effect toward I93M mutant in vitro, thus explaining the 
incomplete penetrance of I93M mutation (Liu et al., 2002). 
Kabuta et al. also showed an aberrant interaction between mutant I93M UCHL1 and 
protein involved in chaperon mediated autophagy (CMA) machinery: LAMP2A, 
Hsp70 and Hsp90. I93M UCHL1 was proposed to be a negative regulator of the 
CMA pathway and to have also a role in the inhibition of α-synuclein shunting to 
lysosomes (Kabuta et al., 2008). 
Recent studies have shown classical Lewy pathology in a deceased sibling of a family 
affected by 193M UCHL1 mutation who developed, in addition to DOPA-responsive 
Parkinsonism, marked cognitive deficits (Leroy et al., 1998). 
From a clinical point of view, UCHL1 has been extensively studied in post mortem 
brains of neurodegenerative diseases. In Alzheimer’s Disease (AD) brains UCHL1 
was also commonly found in neurofibrillary tangles with decreased levels of soluble 
protein (Choi et al., 2003). Downregulation and extensive oxidative modifications 
have been observed in post mortem brains of both AD and PD idiopathic forms 
(Butterfield et al., 2002; Castegna et al., 2002). Aberrant ubiquitin hydrolase and/or 
ligase activity occurring after oxidative modifications and/or downregulation of 
UCHL1 might lead to dysfunction of the neuronal ubiquitination/de-ubiquitination 
machinery, thus causing synaptic deterioration and neuronal degeneration. 
Furthermore, oxidative modification can make UCHL1 itself more resistant to 
proteolysis and promote aggregation into hallmark lesions of AD and PD brains 
(Lowe et al., 1990; Choi et al., 2003). In fact, UCHL1 has been found in 
neurofibrillary tangles and the level of soluble UCHL1 protein was inversely 
proportional to tangle number. These observations together with the lower hydrolytic 
activity shown by oxidized forms of UCHL1 raise the possibility that its role may be 
the de-ubiquitination of posphorylated tau protein and prevention of its aggregation in 
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vivo. Importantly, transduction of Uchl1 protein restored enzymatic and synaptic 
activity in hyppocampal slices treated with oligomeric Ab42 peptides and in APP/Ps1 
mice model of AD (Gong et al., 2006). 
A potential link of UCHL1 with α-synuclein pathology is supported by the 
observation that inhibition of UCHL1 activity in fetal rat ventral mesencephalic 
cultures is associated with α-synuclein aggregates (McNaught et al., 2002). 
Increased intracellular aggregates containing ubiquitinated proteins have been found 
in human SK-N-SH cells after UCHL1 inhibition by prostaglandins (Li et al., 2004). 
These findings suggest that reduced UCHL1 activity impairs Ubiquitin Proteasome 
System (UPS) function and protein degradation, thus facilitating the accumulation of 
abnormal protein aggregates. In line with this, reduced Uchl1 mRNA and protein is 
found in PD and in Dementia with Lewy Bodies (DLB) (Barrachina et al., 2006). 
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Molecular Mechanism of Translational Control 
The mammalian translational machinery is a tightly regulated system composed by 
eukaryotic initiation, elongation, and termination factors that are responsible for the 
recruitment of ribosomes to the 5’cap structure of cytoplasmic RNAs and for the 
following step of polypeptide chain synthesis. 
Two predominant pathways translate mammalian mRNA through cap-dependent and 
independent mechanisms. 
 
 
 
Cap-Dependent Translation 
The rate-limiting step of protein synthesis is translation initiation. During this process 
the small ribosome subunit 40S is loaded on the 7metil-GTP-capped mRNA and 
scans in the 3’ direction for the AUG start codon where the complete ribosome is 
subsequently assembled to begin polypeptide formation. 
The recruitment of small ribosomal subunit requires the assembly of the eukaryotic 
Initiation Factor 4F (eIF4F) complex on the 5’cap structure of mRNA. eIF4E or cap-
recognizing protein binds to the 5’7mG of mRNAs and promotes the assembly of 
eIF4A and eIF4G. The inhibited hyperphosphorylated eukaryotic Initiation Factor 4E-
Binding Protein 1 (4E-BP1) releases eIF4E, allowing eIF4F complex to form. 4E-
BP1 is a target of highly regulated signaling pathways that control its phosphorilation 
status and thus its ability to bind to eIF4E. 
 
Figure 12. Regulating cap-dependent translation initiation. Following 40S ribosomal S6K-
mediated phosphorylation, eIF4B is recruited to the pre-initiation complex and enhances the RNA 
helicase activity of eIF4A. GF, growth factor. Modified from Ma and Blenis, 2009. 
 
 
Some mRNAs contain inhibitory secondary structures at their 5’UTRs. They may 
encode proteins that are involved in promoting cell growth and proliferation. Normal 
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processivity of translational machine requires that highly structured 5’UTR are first 
linearized. This is achieved through an initiation factor belonging to the family of 
RNA helicases, eIF4A which unwinds the RNA as long as the initiation complex is 
forming on the 5’cap of these mRNAs. Basic eIF4A activity is significantly enhanced 
when associated to its regulatory factor eIF4B, a target of 40S ribosomal protein S6 
kinase (S6K). S6K phosphorilates eIF4B near its RNA-binding site, thus promoting 
its association to eIF4A (Fig. 12). Mutant eIF4B that cannot be modified by S6K is 
inactive in vitro, confirming that phosphorilation is both sufficient and necessary for 
its recruitment to the translation-initiation complex. 
 
 
 
Cap-Independent Translation 
RNA genomes of picornaviruses, such as encephalomyocarditis virus (EMCV) and 
poliovirus, have properties that are incompatible with initiation by 5′end–dependent 
scanning. In 1988, it was discovered that picorna viral mRNAs are translated by a 
mechanism, distinct from shunting, that enables ribosomes to initiate translation 
effectively on highly structured regions located within the 5'non-translated region 
(NTRs) (Pelletier et al., 1988). These regions were named Internal Ribosomal Entry 
Sites (IRESs). Picornaviral 5’NTRs can range in length from 610 to 1500 nucleotides, 
are highly structured, and contain multiple nonconserved AUG triplets upstream of 
the initiation codon that should act as strong barriers to scanning ribosomes. 
Interestingly, several cellular oncogenes, growth factors and proteins involved in the 
regulation of programmed cell death, cell cycle progression and stress response 
contain IRES elements in their 5'UTRs. Internal initiation of translation escapes many 
control mechanisms that regulate cap-dependent translation. Thus, a distinguishing 
hallmark of IRES-mediated translation is that it allows for enhanced or continued 
protein expression under conditions where normal, cap-dependent translation is shut-
off or compromised. For instance, IRES elements were found to be active during 
irradiation (Gu et al., 2009), hypoxia (Lang et al., 2002), angiogenesis (Nagamachi et 
al., 2010), apoptosis (Spriggs et al., 2005), and amino acid starvation (Gilbert et al., 
2007). 
The repression of global protein synthesis associated with such stresses is in part a 
consequence of phospholylation of Ser51 on the α subunit of the translation initiation 
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factor eIF2, which is a heterotrimer consisting of α, β, and γ subunits. During one of 
the first step of translation, eIF2 binds to GTP and the initiator Met-tRNAi
Met
 to form 
the Ternary Complex (TC), which subsequently binds to the 40S ribosomal subunit to 
compose the 43S PreInitiation Complex (PIC). In a second step GTP is hydrolyzed; 
for recurring initiation, the GDP must be released and eIF2 charged with fresh GTP. 
This reaction is catalyzed by eIF2β. After phosphorylation of eIF2α subunit of eIF2 
the TC formation is inhibited, leading to a global repression of protein synthesis (Fig. 
13). 
 
 
Figure 13. Recycling of EiF2 by EiF2B and regulation by Eif2A kinases. The γ subunit of eIF2 
binding to GTP is essential for the TC of eIF2, GTP and Met-tRNAi
Met
. During the course of 
translation initiation the GTP bound by eIF2 is hydrolyzed to GDP and eIF2 is released from the 
ribosome in a binary complex with GDP. As eIF2 has a much higher affinity for binding GDP than 
GTP, a guanine-nucleotide exchange factor termed eIF2β is required. 
 
 
Paradoxically, inhibition of eIF2 by phosphorylated eIF2α leads to upregulated 
translation of mRNAs with particular motifs in their 5’UTRs  these motifs are 
recognizable as upstream Open Reading Frames (uORFs) and IRES (Tzamarias et al., 
1989; Vattem and Wek, 2004; Stoneley and Willis, 2004; Komar and Hatzoglou, 
2011). 
In the genome of Saccharomyces cerevisiae a single eIF2α kinase has been found and 
named General Control Non-derepressing 2 (GCN2). GCN2 is activated in response 
to nutrient deprivation and in particular to amino acids starvation (Kimball, 2001). 
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Mammals have 4 different eIF2α kinases: the mammalian ortholog to GCN2, the 
Protein Kinase R (PKR), the Heme-Regulated Inhibitor kinase (HRI), and the PKR-
like endoplasmic reticulum (ER)-localized kinase (PERK). Each of these kinases is 
activated upon distinct stresses: GCN2 after deprivation of essential amino acids, 
PKR after viral infection with double-stranded RNA and interferon response, HRI 
during heme limitation and PERK during ER stress or Unfolded Protein Response 
(UPR). 
Phosphorylation of eIF2α is essential for both the shut-off of global translation and 
recovery from stress. For instance, when unfolded protein accumulates in the lumen 
of ER, activated PERK mediates the phosphorylation of eIF2α. PERK-mediated 
phoshorylation of eIF2α represses the synthesis of proteins targeted to the ER thereby 
minimizing further accumulation of unfolded proteins. Lower cellular availability of 
eIF2α-GTP bound complexes increases the chance that mRNAs with internal AUG 
are translated (Fig. 14). 
 
Figure 14. Kinases as sensors of cellular stress. 
These shown protein kinases are activated following heme-deprivation (HRI), virus infection (PKR), 
ER stress (PER ), and amino acid starvation (GCN2). Subsequent phosphorylation of eIF2α on Ser-51 
inhibits eIF2β and thus impairs general translation. 
 
 
Together, these observations suggest that IRES and uORF mediate the translation 
initiation of certain mRNAs, representing a regulatory mechanism that helps the cell 
cope with transient stress. It is thus reasonable that each of the eIF2α kinases would 
be required for a recovery program specific to its activating stress, hence influencing 
the translation efficiency of different subsets of mRNAs. Moreover, IRES activity 
may also participate in the maintenance of normal physiological processes such as 
adequate synthesis of some proteins during cell cycle progression (Fingar et al., 
2003). 
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Rapamycin 
The ability of a cell to respond to an environmental stress is a fundamental property 
which allows cell survival. Cells respond to changes in environmental conditions by 
altering gene expression and proteins are produced as a consequence of new mRNA 
synthesis. However, translation is a tightly regulated molecular step and it has a 
fundamental role in forming the proteome of a cell. 
To grow and proliferate cells must ensure that sufficient resources are available to 
drive protein production. When amino acids availability becomes limiting, protein 
production has to be down-regulated, keeping the spare energetic resources to 
survive. 
Mammalian cells have evolved a fine mechanism of translational control in response 
to nutrient availability, cellular energy, stress, hormones and growth factors stimuli, 
which targets translational initiation. A key pathway that responds to environmental 
cues and integrates protein synthesis rate with external conditions involves the 
mammalian Target Of Rapamycin (mTOR). mTOR is the catalytic subunit of two 
molecular complexes: mTORC1 and mTORC2. mTORC1 is a serine/threonine 
protein kinase which includes mTOR, Raptor (regulatory-associated protein of 
mTOR) and Mammalian Lethal with SEC13 protein 8 (MLST8) (Fig. 15). 
 
 
Figure 15. Regulating cap-dependent translation initiation. Hypophosphorylated 4E-BPs bind 
tightly to eIF4E, thereby preventing its interaction with eIF4G and thus inhibiting translation. 
mTORC1-mediated phosphorylation of 4EBPs releases the 4E-BP1 from eIF4E, resulting in the 
recruitment of eIF4G to the 5’cap, and thereby allowing translation initiation to proceed. Modified 
from Ma and Blenis, 2009. 
 
 
mTOR signaling is activated downstream to numerous growth stimuli responding 
mainly to the Akt/PI3K pathway. Thus, TOR signaling coordinates cell growth and 
metabolism in response to physiological changes and elicits its control mainly via 
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phosphorilaton of its major downstream targets, 4E-BP1 and S6K. Phosphorilated 
4EBP releases the 4E-BP from eIF4E, resulting in the recruitment of eIF4G to the 
5′cap, and thereby allowing translation initiation to proceed. 
Rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus, which 
binds and inhibits mTOR. Inhibited mTOR prevents further phosphorylation of S6K, 
4E-BP1 and, indirectly, other proteins involved in transcription, translation and cell 
cycle control. 
Inhibition of cap-dependent translation is essential for survival under stress 
conditions. Many cellular stressors result in the rapid cessation of overall cap-
dependent translation and promotion of cap-independent translation of several 
prosurvival factors. Overexpression of the translational inhibitor 4E-BP1 or treatment 
with mTOR inibitor rapamycin has been shown to possess viable therapeutic potential 
for PD (Tain et al., 2009; Liu et al., 2013). 
It has been proved that 4E-BP1 mediates the survival response of cells exposed to 
various stresses (Clemens, 2001; Richter and Sonenberg, 2005). A regulated control 
of translation is believed to be the strategy used by cells to elicit a rapid response to 
toxic insults aiming to immediately change protein synthesis from pre-existing 
mRNAs pools. 
In D. melanogaster PINK1 and parkin mutants exhibit dopaminergic 
neurodegeneration, locomotor deficits and mitochondrial dysfunction, representing a 
reliable animal model of PD. A genetic screening on D. melanogaster mutants has 
identified Thor as a modifier capable to influence the Parkin-/- genotype. Thor 
encodes for the sole orthologue of the mammalian 4E-BP1. Loss of D. melanogaster 
4E-BP1 Thor markedly reduced the viability of double mutants for parkin and 
PINK1. On the contrary, overexpression of 4E-BP1 was sufficient to suppress all the 
pathologic phenotype in Parkin/PINK1 double mutants, included neurodegeneration 
(Tain et al., 2009). The same protective effect in vivo is achieved by rapamycin-
driven pharmacological inhibition of TOR. 
Rapamycin has been recently found to provide neuroprotection in PD models 
(Malagelada et al., 2010). Primary neurons pre-exposed to rapamycin are protected by 
different neurotoxins that are known to recapitulate PD pathogenesis. More 
importantly, the infusion of rapamycin in the brain of mice treated with the PD 
mimicking drug MPTP (1-metil 4-phenil 1,2,3,6-tetrahydro-piridin) rescues neurons 
from undergoing degeneration. 
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The neuroprotection is exerted at different levels: 1) Rapamycin promotes autophagy 
in neurons; protein aggregates and organelles damaged by PD-mimicking neurotoxins 
would be cleared by autophagic process; 2) Rapamycin suppresses the expression of 
pro-cell death proteins known to induce neuronal apoptosis; one of these proteins is 
RTP801, a transcription factor that is induced during PD and neuronal oxidative 
stress (Ryu et al., 2002; Malagelada et al., 2006); 3) Rapamycin maintains the 
activation status of neuroprotective signaling pathways in neurons such as the pro-
survival Akt pathway (Malagelada et al., 2008). Importantly, rapamycin treatment is 
also able to rescue mitochondrial defects in parkin-mutant PD patient cells (Siddiqui 
et al., 2012). 
Other studies have shown that rapamycin significantly reduces the toxic buildup of 
protein aggregates such as amyloid beta and huntingtin proteins in vivo and in vitro 
models of AD and Huntington’s Disease (HD) (Yu et al., 2005; Sarkar and 
Rubinsztein, 2008). 
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In Vitro Transcription and Translation Systems 
Cell-free protein synthesis (CFPS) is not a new concept and it is based on the 
demonstration that cell integrity is not necessary for protein translation. Instead of 
relying on living cells, CFPS is carried out in an artificial buffer supplemented with a 
crude cell lysate, an energy supply, amino acids, and an exogenously mRNA or DNA 
template. The biggest advantage is that CFPS offers the quickest way to link a 
phenotype (protein) to a genotype (gene). 
Indeed, most of the knowledge on the genetic code, mRNA, ribosome functions, 
protein factors involved in translation, translation stages including initiation, 
translational control, and co-translational protein folding, was obtained thanks to the 
use of cell-free systems. Like PCR, which uses cellular replication machinery to 
create a DNA amplifier, cell-free protein synthesis is emerging as a transformative 
technology with broad applications in protein engineering, biopharmaceutical 
development, and post-genomic research. 
In order to produce high quantity of biologically active proteins in vitro, cell culturing 
and transfection of an expression vector carrying cDNA are time consuming, and 
undesirable proteolytic processing might happen in the mammalian cell culture 
system. 
The protein expression field has traditionally been dominated by cell-based 
expression systems, initially including both conventional (Escherichia coli, 
Saccharomyces cerevisiae) and non-conventional (e.g., Pichia pastoris, Thermus 
thermophilus) host organisms that have been developed as ‘cell factories’. 
However, to fulfill their function proteins must adopt a precise three-dimensional 
conformation, the native state, acquired during cellular protein folding. This process 
is universally conserved in all organisms and enables bacteria to produce large 
amounts of human proteins. Although Escherichia coli is the simplest and by far the 
most widely used organism, the folding pathway of many recombinant proteins is 
often impaired in that host. Consequently, the misfolded polypeptides aggregate and 
form inclusion bodies instead of the native protein. 
In this scenario, cell-free protein synthesis has rapidly emerged as an important 
complementary approach, rivaling cell-based protein production in terms of both 
convenience and scalability, and becoming widely recognized as a valuable tool for 
protein engineering (Kai et al., 2012). 
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Since viral RNA polymerases became commercially available, in vitro 
transcription/translation systems have allowed us to conveniently produce 
recombinant proteins of interest from cDNA. Such translation systems include the 
rabbit reticulocyte lysate system (Asselbergs et al., 1980), Hela cell lysate system 
(Mikami et al., 2008), wheat germ extract system (Lodish and Rose, 1977), and insect 
cell extract (Tarui et al., 2000). Some of the translation mixtures are further 
supplemented with T7 RNA polymerase and nucleotides, which enables the synthesis 
of recombinant protein from cDNA in a single tube within a few hours. Furthermore, 
programming a cell-free system with PCR products was made possible by adding a 
potent inhibitor of exonucleases, naturally present in bacterial lysate, thus increasing 
considerably the lifetime of linear DNA templates. With this development, all 
techniques of mutagenic PCR, used in protein engineering (site-directed or random 
mutagenesis, exchange exchange of codons, insertion or deletion, gene fusion, etc.), 
can be directly coupled with protein production (Burks et al., 1997). 
The choice of a translation mixture over the others is imposed by the aim of the 
following analysis. For instance, Wang et al. have recently reported that among wheat 
germ extract, HeLa cell lysate, and rabbit reticulocyte lysate, only the latter was able 
to produce a biologically active neurotrophic factor. They presumed that the tertiary 
structure of the translation product(s) in the wheat germ extract and Hela cell lysate 
significantly differ from those in the reticulocyte lysate. Thus, the reticulocyte lysate 
translation system can be applied to high-throughput screening of active gene 
products (Wang et al., 2011b). 
In addition to structural studies, the possibility of incorporating unnatural and 
chemically modified amino acids into proteins synthesized in cell-free systems raises 
new possibilities in functional studies, protein engineering and pharmaceutical 
research. The absence of cells permits the preparative scale synthesis of cytotoxic 
proteins and polypeptides, including various cell regulators and other factors crucial 
for cell life. 
In addition to the principal contributions of the cell-free method to the basic science, 
possibilities for technological applications of cell-free translation systems have arisen. 
The development of continuous cell-free translation systems with perpetual supply of 
consumable substrates and removal of reaction products made the process of in vitro 
synthesis of individual proteins sustainable and productive (Spirin, 2004). 
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Advances in cell-free protein synthesis in recent years, particularly the ability to 
reconstitute protein synthesis from well-defined, purified components, has 
transformed the approach from a specialized analytical tool to a powerful preparative 
method with broad applicability. The Protein synthesis Using Recombinant Elements 
(PURE) approach to cell-free protein synthesis is based on modular reconstitution of 
the translational machinery of the cell from affinity purified protein components 
(Shimizu et al., 2005), including initiation factors, elongation factors, release factors, 
ribosome recycling factors, 20 aminoacyl tRNA synthetases, methionyl tRNA 
formyltransferase and pyrophosphatase, all bearing a 6 x His tag that can be utilized 
in ‘reverse purification’ of products, extracting the tagged proteins by metal affinity 
chromatography. These recombinant components are combined with ribosomes and 
tRNAs isolated from specially engineered E. coli strains, together with all of the 
necessary NTPs and amino acids, an ATP-generating catalytic module and 
Recombinant T7 RNA Polymerase (RNAP), creating a self-contained reaction system 
that can be programmed for protein synthesis using a variety of DNA templates. The 
advantages of the PURE systems include reduced levels of contaminating proteases, 
nucleases, and phosphatases, greater reproducibility resulting from more defined 
chemistry, and the flexibility of a modular system. Because it is modular, the PURE 
system supports a variety of modifications for specialized applications, including 
ribosome display and site-selective incorporation of non-natural amino acids 
(Whittaker, 2012). 
  
50 
 
MATERIALS AND METHODS 
Plasmids 
AS Uchl1 ΔA (ΔAlu, 1000˗1045) mutant was obtained by subsequent cloning of PCR 
fragment I (NheI-EcoRI site) and PCR fragment II (EcoRI-HindII site) into 
pcDNA3.1(˗). Primers used to obtain fragments I and II from AS Uchl1 were: 
PCR fragment I: For mAS Uchl1 fl: 5’-ACAAAGCTCAGCCCACACGT-3’ 
 Rev pre-SINE B2: 5’-CAATGGATTCCATGT-3’ 
PCR fragment II: For post-ALU: 5’-GATATAAGGAGAATCTG-3’ 
 Rev mAS Uchl1 fl: 5’-CATAGGGTTCATT-3’ 
AS Uchl1 ΔS (ΔSINEB2, 764˗934) mutant was obtained with a similar strategy than 
AS Uchl1 ΔA and the following primers: 
PCR fragment I: For mAS Uchl1 fl: 5’-ACAAAGCTCAGCCCACACGT-3’ 
 Rev pre-SINE B2: 5’-CAA TGGATTCCATGT-3’ 
PCR fragment II: For post-SINE B2: 5’-GAATTCCTCCAGTCTCTTA-3’ 
 Rev mAS Uchl1 fl: 5’-CATAGGGTTCATT-3’ 
AS Uchl1 ΔAS (ΔAlu+SINEB2, 764˗1045) mutant was obtained with a similar 
strategy than AS Uchl1 ΔA and the following primers: 
PCR fragment I: For mAS Uchl1 fl 5’-ACAAAGCTCAGCCCACACGT-3’ 
 Rev pre-SINE B2 5’-CAATGGATTCCATGT-3’ 
PCR fragment II: For post-ALU 5’-GATATAAGGAGAATCTG-3’ 
 Rev mAS Uchl1 fl 5’-CATAGGGTTCATT-3’ 
AS Uchl1(ASf) (flipped Alu+SINEB2): PCR fragment obtained with the following 
primers was cloned in the unique EcoRI site of AS Uchl1 ΔAS: 
For SINE B2 inside: 5’-TGCTAGAGGAGG-3’ 
Rev Alu inside: 5’-GTCAGGCAATCC-3’ 
AS Uchl1(Sf) (flipped SINEB2): PCR fragment obtained with the following primers 
was cloned in the unique EcoRI site of AS Uchl1 ΔS: 
For SINE B2 inside: 5’-TGCTAGAGGAGG-3’ 
Rev SINE B2 flip: 5’-AAAGAGATGGC-3’ 
AS Uxt was amplified by PCR starting from FANTOM clone 4833404H03 (GenBank 
AK029359.1) and cloned into pcDNA3.1(-) using XbaI and HindIII restriction sites 
with the following primers: mAS Uxt F: 5’-CAACGTTGGGGATGACTTCT-3’ 
 mAS Uxt R: 5’-TCGATTCCCATTACCCACAT-3’ 
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AS Uchl1-73bp was obtained by annealing and extension of two 3’end overlapping 
oligonucleotides to generate the 73 bp antisense Uchl1 overlap region. Annealed 
fragment was obtained with: 
AS Uchl1 73 bp forward: 
5’-TCGGGGTTAATCTCCATCGGCTTCAGCTGCATCTTCGCGGATGGCACC-3’ 
AS Uchl1 73 bp reverse: 
5’-CGGCTCCTCGGGTTTGTGTCTGCAGGTGCCATCCGCGAAGATGCAG-3’ 
Fragment was digested with XhoI and EcoRV and ligated into Δ5’ AS Uchl1 deletion 
mutant (Carrieri et al., 2012). 
AS SCR(73 bp) mutant was obtained with a similar strategy as AS Uchl1-73bp. The 
annealing extension was performed with oligonucleotides with scrambled (SCR) 
sequence. 
AS SCR forward: 
5’-CATCACCCCAAGAAAAGCGGGAACGGTAGCTGGGTCTTGTTAAGATT-3’ 
AS SCR reverse: 
5’-CCTCGTTCCGATGGTTAAGACTCGGAATCTTAACAAGACCCAG-3’ 
AS GFP plasmid was generated with a similar strategy as AS Uchl1-73bp. Seventy-
two base pairs corresponding to nucleotide ˗40/+32 with respect to the ATG of GFP 
coding sequence in pEGFP-C2 vector (Clontech) were chosen as target sequence for 
artificial antisense DNA generation. 
GFP antisense forward: 
5’-CCGGTGAACAGCTCCTCGCCCTTGCTCACCATGGTGGCGACCGGTAGC-3’ 
GFP antisense reverse: 
5’-TAGTGAACCGTCAGATCCGCTAGCGCTACCGGTCGCCACCATGGTGA-3’ 
 
Cells 
MN9D cells were obtained from Prof Michael J. Zigmond at University of Pittsburg. 
Cells were seeded in 100-mm dishes in Dulbecco’s modified Eagle’s (DMEM) 
medium containing 10% fetal bovine serum (Invitrogen) supplemented with penicillin 
(50 units/ml) and streptomycin (50 units/ml). For experiments, cells were plated and 
grown overnight; approximately 50% confluent cells were treated with 1 μM 
rapamycin (R0395, Sigma) or DMSO vehicle for 45’. 
For the establishment of stable cell lines (shRNA -15/14, shRNA scrambled, pcDNA 
3.1- and AS Uchl1DSINEB2), MN9D cells were seeded in 100-mm Petri dishes and 
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transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instruction. Stable clones were selected by 500 mM neomycin (N1142, Sigma). HEK 
cells (Sigma) were cultured under standard condition in DMEM containing 10% fetal 
bovine serum supplemented with antibiotics. 
HEK cells (Sigma) were cultured under standard condition in DMEM containing 10% 
fetal bovine serum supplemented with antibiotics. 
Transient transfections were done with Lipofectamine 2000 (Invitrogen). For all 
experiments, S and AS plasmids were transfected at 1:6 ratio. 
 
qRT-PCR 
Total RNA was extracted using Trizol reagent (Invitrogen) according to 
manufacturer’s instructions. Purified RNA was subjected to DNase I treatment 
(Ambion) and 1μg was retro-transcribed using iScript cDNA Synthesis Kit (BioRad). 
qPCR was carried out using SYBR Green fluorescence dye (2X iQ5 SYBR Green 
supermix, BioRad). GAPDH and β-actin were used as normalizing controls in all 
experiments. The amplified transcripts were quantified using the comparative Ct 
method: relative expression in each sample was calculated by the formula 2^ΔΔCt 
and the differences in gene expression were presented as normalized fold expression. 
Below are the used primers: 
Gapdh F: 5’-GCAGTGGCAAAGTGGAGATT-3’ 
Gapdh R: 5’-GCAGAAGGGGCGGAGATGAT-3’ 
Beta-actin F: 5’- CACACCCGCCACCAGTTC-3’ 
Beta-actin R: 5'- CCCATTCCCACCATCACACC-3’ 
Uchl1 F: 5’-CCCGCCGATAGAGCCAAG-3’ 
Uchl1 R: 5’-ATGGTTCACTGGAAAGGG-3’ 
AS Uchl1 F: 5’CTGGTGTGTATCTCTTATGC-3’ 
AS Uchl1 R: 5’CTCCCGAGTCTCTGTAGC-3’ 
AS Uchl1 overlap F: 5’-GCACCTGCAGACACAAACC-3’ 
AS Uchl1 overlap R: 5’-TCTCTCAGCTGCTGGAATCA-3’ 
GFP F: 5’-GCCCGACAACCACTACCTGAG-3’ 
GFP R: 5’-CGGCGGTCACGAACTCCAG-3’ 
hUCHL1 S: 5’-GCCAATAATCAAGACAAAC-3’ 
hUCHL1 AS: 5’-CATTCGTCCATCAAGTTC-3’ 
hAS UCHL1 S: 5’-AAACCCATCCTTTCACCATCC-3’ 
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hAS UCHL1 AS: 5’-TTCCTATCTTCAGCCACATCAC-3’ 
AS Uxt F: 5’-CAACGTTGGGGATGACTTCT-3’ 
AS Uxt R: 5’-TCGATTCCCATTACCCACAT-3’ 
Uxt F: 5’-TTGAGCGACTCCAGGAAACT-3’ 
Uxt R: 5’-GAGTCCTGGTGAGGCTGTC-3’ 
 
Western Blot 
Cells were lysed in 2X SDS sample buffer. Proteins were separated in 15% SDS–
polyacrylamide gel and transferred to nitrocellulose membranes. Immunoblotting was 
performed with the following primary antibodies: anti-UCHL1 (3524, Cell 
Signaling), anti-UXT (11047-1-AP, Proteintech Group), anti-GFP (A6455, 
Invitrogen), anti-FLAG (F7425, Sigma–Aldrich), and anti-β-Actin (A5441, Sigma). 
For the mTOR pathway: anti-phospho-p70 S6 kinase (Thr 389) (9234), anti-phospho-
4E-BP1 (Ser 65) (9451), anti-p70 S6 kinase (9202), anti-4E-BP1 (9452), were all 
purchased from Cell Signaling. Signals were revealed after incubation with 
recommended secondary antibodies conjugated with horseradish peroxidase by using 
enhanced chemiluminescence for UCHL1 (WBKLS0500, Millipore Immobilion 
Western Chemioluminescent HRP substrate) and ECL detection reagent (RPN2105, 
GE Healthcare). 
 
Cellular Fractionation 
The protocol for nucleo-cytoplasmic fractionation was adapted from Wang et al 2006 
and the subcellular enrichment was confirmed by detection of nuclear and 
cytoplasmic proteins. RNA was extracted using Trizol reagent (Invitrogen) according 
to manufacturer’s instructions and subjected to DNAse I treatment (Ambion). 
 
Polysomes Profiles 
Polysomes profiles were obtained using sucrose density gradients. MN9D cells were 
treated with 1 μg/ml rapamycin for 35’, then with 100 μg/ml cycloheximide for 10’ 
prior lysis in 150 μl lysis buffer (50 mM Tris-HCl pH7.5, 100 mM NaCl, 30 mM 
MgCl2, 100 μg/ml cycloheximide, 0.1% NP-40, 40 U/ml RNasin®, protease 
inhibitors cocktail). Whole cell extracts were clarified at 15000g for 10’ at 4°C. The 
equivalent of 5-10 absorbance units at 254 nm of the clarified cell extract was layered 
onto 15%-55% (w/v) sucrose gradient (50 mM Tris/acetate pH 7.5, 50 mM NH4Cl, 
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12 mM MgCl2 and 1 mM DTT) and centrifuged at 39000 rpm for 210’ in a Beckman 
SW41Ti rotor at 4°C. The gradient was pump out by upward displacement and 
absorbance at 254 nm was monitored using BioLogic LP software (Bio-Rad). 
Fractions of 1 ml were collected, 1 ml Trizol reagent (Invitrogen) was added and, 
RNA was extracted following manufacturer’s instructions. A fixed volume of each 
RNA sample was then retro-transcribed and percentage of mRNA in each fraction 
was calculated as relative Ct value to total RNA. 
 
Pulse Labelling and Immunoprecipitation. 
To monitor de novo protein synthesis, HEK cells were transiently transfected with 
pEGFP-C2 plasmid (Clontech) in combination with antisense GFP or empty control 
vector. After 24 hours, medium was replaced with methionine/cysteine-free DMEM 
for 1 hour. Then, cells were labeled with 100 μCi/ml of [35S]methionine/cysteine 
(EasyTag, Perkin-Elmer) for 1 hour. Labeled cells were collected, lysed in RIPA 
buffer (150 mM NaCl, 50 mM Tris pH8, 1 mM EDTA, 1% NP40, 0.5% deoxycholic 
acid and 0.1% SDS) and used for immunoprecipitation with anti-GFP antibody 
(Invitrogen) overnight. Immune complexes were isolated with protein G-sepharose 
beads (Amersham) and separated on 10% SDS–PAGE. Newly translated GFP was 
visualized by autoradiography. Densitometric analysis was performed on high-
resolution images with Photoshop-CS5. Normalization was obtained relative to input. 
 
Northern Blot. 
500 μl of polysome fractions were digested with 100 μg/ml proteinase   in 1% SDS 
and 10 μg glycogen (Invitrogen) at 37°C for 1 hour. RNA was obtained by 
phenol/chloroform extraction and resuspended in formaldehyde/formamide MOPS 
buffer. Samples were incubated for 5’ at 65°C before being loaded into formaldehyde 
1% agarose gel and run at 90V for 4 hours at 4°C. RNA was transferred onto 
Amersham Hybond-XL nylon membranes and UV-crosslinked. A Uchl1-specific 
RNA probe complementary to the distal 600 bps of mouse Uchl1 cDNA was in vitro 
transcribed in the presence of 50 μCi of α-32P-UTP (Perkin-Elmer). After treatment 
with DNase I (Ambion), the radiolabelled riboprobe was purified on RNeasy columns 
(Qiagen). Membranes were pre-hybridized for 3 hours at 65°C with NorthernMax 
prehybridization/hybridization buffer (Ambion) supplemented with 50 μg/ml salmon 
sperm DNA (Invitrogen), and hybridized with Uchl1 riboprobe overnight at 65°C in 
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the same buffer. After extensive washes (most stringent conditions were 0.2X 
SSC/0.1% SDS at 65°C), membranes were exposed to autoradiography at ˗80°C with 
intensifying screens. 
 
Uncoupled In Vitro Transcription and Translation Assay 
Plasmids were linearized by HindIII digestion and column purified prior to in vitro 
transcription with mMESSAGE mMACHINE® T7 Kit (Ambion). After treatment 
with DNase I (Ambion) the RNA was purified on RNeasy columns (Qiagen). 
The obtained RNA was added to commercially available lysates for in vitro 
translation following manufacturer’s instruction: Rabbit Reticulocyte Lysate System, 
TnT® T7 Insect Cell Extract Protein Expression System, and Wheat Germ Extract 
were all purchased by Promega. Produced proteins were detected by Western Blot 
with anti-GFP (A6455, Invitrogen) antibody. Signals were revealed after incubation 
with recommended secondary antibodies conjugated with horseradish peroxidase by 
using ECL detection reagent (RPN2105, GE Healthcare). 
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PRELIMINARY DATA OF PROFESSOR S. GUSTINCICH LABORATORY 
from Claudia Carrieri’s Thesis “Uchl1 Protein Synthesis Upon Rapamycin 
Treatment Involves Its Antisense RNA Through Embedded SINEB2 Repeat”. 
Among the mouse synthenic genomic loci of genes associated to PD a spliced long 
noncoding (lncRNA) transcript (Rik6430596G22 – GenBank AK078321.1) was 
identified in Uchl1 gene mapping in antisense direction to its coding counterpart. This 
5’ head to head transcript that initiates within the second intron of Uchl1 mRNA and 
overlaps its first 73 bps including the ATG codon (-40/+33 from ATG) was named 
antisense Uchl1 (AS Uchl1) (Fig. 16). 
 
Figure 16. Uchl1/AS Uchl1 genomic organization. Uchl1 exons are in black  3’ and 5’UTRs are in 
white; AS Uchl1 exons are in grey; repetitive elements are in red (Alu) and blue (SINEB2); introns are 
indicated as lines. 
 
 
To elucidate the expression pattern of Uchl1 sense/antisense (S/AS) pair several 
neuronal cell lines, a panel of mouse adult tissues and macroscopically dissected 
brain regions were analyzed. AS Uchl1 was expressed in MN9D dopaminergic cells 
while it was absent in non dopaminergic cell lines. In the mouse adult brain AS Uchl1 
expression was restricted to the ventral midbrain and cortex. In particular AS Uchl1 
was enriched in dopaminergic cells, where the two transcripts were localized in 
different subcellular compartments: mature Uchl1 mRNA was mainly present in the 
cytoplasm, while AS Uchl1 was enriched in the nucleus. 
Moreover AS Uchl1 and Uchl1 were downregulated in neurochemical models of PD 
as expected from the literature on PD post-mortem brains which reported Uchl1 
protein downregulation and inactivation. 
Transient overexpression of antisense Uchl1 in MN9D cells caused no significant 
change in endogenous Uchl1 mRNA expression. Notably, a strong and reproducible 
upregulation of Uchl1 protein was detected suggesting that AS Uchl1 regulates 
UCHL1 expression at a post-transcriptional level (Fig. 17). 
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a          b  
Figure 17. AS Uchl1 regulates Uchl1 translation. a, AS Uchl1-transfected dopaminergic MN9D 
cells show increased levels of endogenous Uchl1 protein relative to empty vector control, with 
unchanged mRNA quantity. b, Increasing doses of transfected AS Uchl1 titrate quantity of translated 
Uchl1 protein in HEK 293T cells. No changes in Uchl1 mRNA levels are detected. Data in a and b 
indicate mean ± s.d., n ≥ 3. 
 
 
To identify sequences and/or structural elements of AS Uchl1 mRNA that elicit its 
functional activity on Uchl1 protein, deletion mutants were produced and tested in 
MN9D cells as well as in co-transfection in HEK cells. Δ5’ AS Uchl1 lacked the first 
exon cointaining the 5’sequence overlapping Uchl1, while Δ3’ AS Uchl1 did not 
contain the last three exons of the antisense transcript (Fig. 18a). Neither the Δ3’ nor 
the Δ5’ transcripts were able to upregulate endogenous Uchl1 protein levels in 
dopaminergic MN9D (Fig. 18b) and in cotransfection in HEK cells (Fig. 18c). 
Titration of the endogenous level of Uchl1 in transfected MN9D cells was evaluated 
with qRT-PCR, and no significant change in its mRNA expression was noticed. 
These results suggest that both 5’ and 3’ components are required for AS Uchl1 
function. 
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a      b  
c         
Figure 18. Full length AS Uchl1 is required for UCHL1 upregulation. a, Scheme of Δ5’ or Δ3’ 
deletion mutants is shown. b, Full-length (FL) AS Uchl1 is required for regulating endogenous 
UCHL1 level in MN9D cells; units for numbers along the left of gels indicate kDa. c, FL AS Uchl1 is 
required for regulating overexpressed UCHL1 level in HEK cells (left panel); units for numbers along 
the left of gels indicate kDa. qRT-PCR (right panel) from MN D cells transfected with Δ5’ and Δ3’ 
AS Uchl1 mutants; relative abundance of endogenous Uchl1 mRNA and overexpressed deletion 
mutants are shown. Data indicate mean ± s.d., n ≥ 3. 
 
 
Among several stressors that have been implicated in PD pathogenesis inhibition of 
mTOR by rapamycin treatment of MN9D cells induced an increase in UCHL1 levels 
similar to the overexpression of AS Uchl1. Rapamycin treatment did not affect Uchl1 
mRNA level and the stability of its protein (Fig. 19). At a subcellular analysis 
rapamycin substantially induced AS Uchl1 shuffle to the cytoplasm. This 
redistribution was confirmed by a concomitant decrease in its nuclear steady-state 
levels, and by the absence of any de novo transcription (Fig. 19). Uchl1 mRNA 
showed no change in subcellular distribution, de novo transcription or total cellular 
content (Fig. 19), suggesting that AS Uchl1 localization can be regulated by the 
mTOR pathway, and its cytoplasmic level correlates with the expression of Uchl1 
protein. 
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a  b   
Figure 19. Rapamycin induction of Uchl1 protein and AS Uchl1 shuffling. a, Uchl1 protein level is 
increased in rapamycin-treated MN9D cells. Rapamycin inhibition of mTOR pathway is verified with 
anti-p-p70S6K and anti-p-4E-BP1 antibodies. b, AS Uchl1 translocates from the nucleus (left) to the 
cytoplasm (right) upon rapamycin treatment in MN9D cells. mRNA levels were measured by qRT-
PCR with 5’ or 3’ primers. Data indicate mean ± s.d., n ≥ 3. **p < 0.01; ***p < 0.005. 
 
 
 
Furthermore, a causal link between rapamycin induction of Uchl1 protein and AS 
Uchl1 expression was proved through silencing of AS Uchl1 expression in MN9D 
cells, indicating that AS Uchl1 mediates rapamycin-induced Uchl1 protein 
upregulation (Fig. 20). 
a        b  
Figure 20. AS Uchl1 is required for rapamycin-induction of Uchl1 protein. a, Silencing AS Uchl1 
transcription (shRNA) in MN9D cells does not affect Uchl1 mRNA levels. Data indicate mean ± s.d., 
n≥ 3. **p < 0.01; ***p < 0.005. b, Uchl1 protein level is increased in rapamycin-treated MN9D cells 
but not in AS Uchl1-silenced MN9D cells. Rapamycin inhibition of mTOR pathway is verified with 
anti-p-p70S6K and anti-p-4E-BP1 antibodies. 
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RESULTS 
Analysis of Polysome Association upon Rapamycin Treatment. 
Association of Uchl1 mRNA to polysomes was then monitored upon rapamycin 
treatment to assess the role of translation in Uchl1 protein induction. MN9D cells 
were treated with Rapamycin 1μg/ml for 45’ and with vehicle DMSO as control. 
Cytoplasmic extracts were prepared and fractionated through sucrose gradients. Nine 
fractions were collected from each gradient while recording the absorbance profile. 
Distribution of specific transcripts was assayed with qRT-PCR. Uchl1 mRNA was 
found increased in fraction 8 upon rapamycin treatment, showing an enhanced 
polysome association (Fig. 21). mRNA of β-actin show a pattern similar for DMSO 
and rapamycin treated cells since no variation of polysomal association can be 
observed in the different growth conditions (Fig. 21). 
 
a   b  
Figure 21. Uchl1 associated with polysomal fractions upon rapamycin treatment. a, qRT-PCR for 
Uchl1, and β-Actin was performed on RNA extracted from 9 sucrose gradient fractions of MN9D cells 
treated with rapamycin or vehicle alone (DMSO), as indicated. Association with each fraction is shown 
as percentage of total mRNA. Absorbance profile is outlined in the background of each plot. b, 
Inhibition of mTOR was verified with anti-p-p70S6K (Thr389) and anti-p-4E-BP1 (Ser65) antibodies. 
 
 
The association of Uchl1 mRNA with polysomes was then monitored by northern 
blotting. MN9D cells were treated with rapamycin 1μg/ml for 45’ and with vehicle 
DMSO as control. Cytoplasmic extracts were prepared and fractionated through 
sucrose gradients. Nine fractions were collected from each gradient while recording 
the absorbance profile. The purified RNA was blotted and Uchl1 mRNA was detected 
by radiolabelled RNA probe generated through in vitro transcription of the distal 600 
bps of Uchl1 transcript. In basal conditions, Uchl1 mRNA was associated with 
translating ribosomes. Rapamycin treatment induced a significant shift of Uchl1 
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mRNA to heavier polysomes (Fig. 22), consistent with an enhanced rate of translation 
initiation; this increase of Uchl1 mRNA association to heavier polysomes did not 
occur in control cells. The analysis of the whole polysomal profile showed a clear 
shift of Uchl1 mRNA toward the heaviest fraction upon rapamycin treatment, 
confirming the redistribution previously detected by qRT-PCR (Fig. 22). 
 
a  
 
b      c     
 
Figure 22. Uchl1 mRNA increases association to heavy polysomes upon rapamycin treatment of 
MN9D cells. a, RNA purified from 9 sucrose gradient fractions was used for Northern Blot analysis 
with radioactive riboprobes for Uchl1 mRNA. b, Quantification of Uchl1 mRNA signals is obtained by 
the addition of the fractions corresponding to the light subpolysomal mRNPs and the heavy polysomes 
from three replica. Data indicate mean ± s.d. *p < 0.05. c, Total protein lysates from the same cell 
preparation were analyzed for the level of expression of UCHL1 and β-Actin; inhibition of mTOR was 
verified with anti-p-p70S6K (Thr389) antibody. 
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AS Uchl1 Causes Uchl1 Protein Upregulation in an Embedded SINEB2-
Dependent Fashion. 
Repeatmasker analysis of AS Uchl1 revealed the presence of two embedded 
repetitive sequences, SINEB2 and Alu, within the 3’ half of the transcript. Therefore, 
additional deletion mutants were synthesized to assess the role of these embedded 
repetitive elements in Uchl1 protein upregulation: the ΔSINEB2+Alu (ΔAS) (764-
1045), the ΔSINEB2 (ΔS) (764-934) and the ΔAlu (ΔA) (1000-1045). While the 
ΔAlu mutant showed a comparable effect on Uchl1 protein upregulation as full length 
AS Uchl1, the ΔSINEB2+Alu and the ΔSINEB2 mutants were unable to do so 
proving a functional role of the embedded SINEB2 (Fig. 23). 
 
a  
 
b  
c     
Figure 23. AS Uchl1 regulates Uchl1 translation via embedded SINEB2. a, Scheme of mutants is 
shown in 5’ to 3’ orientation. ΔA, ΔAlu; ΔS, ΔSINEB2; ΔAS, ΔAlu1+SINEB2; Sf, SINEB2 flipped; 
ASf, Alu1+SINEB2 flipped. b, Inverted SINEB2 is sufficient to control endogenous UCHL1 levels in 
MN9D cells. Units for numbers along the left of gels indicate kDa. c, Endogenous Uchl1 mRNA levels 
are not altered by overexpression of AS Uchl1 mutants. In qRT-PCR from MN9D cells transfected 
with ΔA, ΔS and ΔAS AS Uchl1 mutants relative abundance of endogenous Uchl1 mRNA and over-
expressed deletion mutants are shown. Data indicate mean ± s.d., n ≥ 3. 
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No change in Uchl1 mRNA level was observed. Since the deletion mutant ΔSINEB2 
lacks 170 nucleotides potentially impairing AS Uchl1 RNA secondary structure, a 
mutant was produced with the SINEB2 sequence flipped in between nucleotide 764-
934. Interestingly, SINEB2 flip was unable to increase Uchl1 protein levels in 
transient transfection thus proving the orientation-dependent activity of the SINEB2 
domain (Fig. 23). Together, these data indicated that AS Uchl1 function of translation 
enhancer resided in the SINEB2 sequence embedded in its 3’ tail and in its inverted 
orientation. Furthermore, ΔSINEB2 AS Uchl1 demonstrated to have a negative 
dominant effect on full length AS Uchl1 endogenously expressed in MN9D cells. 
 
 
 
Rapamycin Causes Uchl1 Protein Upregulation in an Embedded SINEB2-
Dependent Fashion. 
As previously demonstrated in Professor S. Gustincich laboratory, the effects of 
rapamycin on Uchl1 protein levels were concomitant to AS Uchl1 RNA redistribution 
from the nucleus to the cytoplasm and UCHL1 induction required the expression of 
AS Uchl1. As an indipendent model, stable cell lines constitutively expressing 
ΔSINEB2 AS Uchl1 and empty vector as control were established taking advantage 
of the dominant negative properties of this deletion construct on the activity of the 
endogenous full length AS Uchl1 in MN9D cells. 
a      b  
Figure 24. Deletion of embedded SINEB2 in AS Uchl1 inhibits rapamycin-induced Uchl1 protein 
upregulation. a, Expression of ΔSINEB2 AS Uchl1 does not affect Uchl1 mRNA levels in 
comparison to pcDNA3.1 control cells. Data indicate mean ± s.d., n ≥ 3. b, Deletion of embedded 
SINEB2 from AS Uchl1 inhibits rapamycin-induced Uchl1 protein upregulation. Inhibition of mTOR 
was verified with anti-p-p70S6K (Thr389) and anti-p-4E-BP1 (Ser65) antibodies. 
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MN9D cells were stably transfected with ΔSINEB2 AS Uchl1 and pcDNA3.1 as 
control and ΔSINEB2 AS Uchl1 was checked by qRT-PCR. Expression of ΔSINEB2 
AS Uchl1 does not affect Uchl1 mRNA levels in stably transfected MN9D cells (Fig. 
24). As expected, when polyclonal stable MN9D cells for empty vector pcDNA3.1 
were treated with rapamycin, Uchl1 protein was found increased. In presence of the 
dominant negative form of ΔSINEB2 AS Uchl1, this upregulation was no longer 
visible (Fig. 24). These results suggested that deletion of embedded SINEB2 from AS 
Uchl1 is sufficient to inhibit rapamycin-induced Uchl1 protein upregulation. 
Taking advantage of MN9D cells stably transfected for ΔSINEB2 AS Uchl1 we 
analyzed the polysomal association of Uchl1 mRNA upon rapamycin treatment to 
further assess if translation of Uchl1 mRNA was affected by the deletion of 
embedded SINEB2 of AS Uchl1. 
 
a  
b  
Figure 25. Uchl1 mRNA association to heavy polysomes depends on a functional AS Uchl1. qRT-
PCR for a, control pcDNA3.1 stable MN9D cells (Ctr) and b, mutant ΔSINEB2 AS Uchl1 stable 
MN9D cells treated with rapamycin or vehicle alone (DMSO) was performed on RNAs purified from 
14 sucrose gradient fractions. Association with each fraction is shown as linear plot of the percentage 
of total RNA  the plot is superimposed on the absorbance proﬁle of the gradient. 
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MN D cells were treated with rapamycin 1μg/ml for 45’ and with vehicle DMSO as 
control. Cytoplasmic extracts were prepared and fractionated through sucrose 
gradients. Fourteen fractions were collected from each gradient while recording the 
absorbance profile. Distribution of specific transcripts was assayed with qRT-PCR. 
Uchl1 mRNA was found increased in fraction 12 of 1.54 fold upon rapamycin 
treatment, showing an enhanced polysome association in control pcDNA3.1 stable 
MN9D cells (Fig. 25). mRNAs of β-Actin show a pattern similar for DMSO and 
rapamycin treated cells since no variation of polysomal association can be observed 
in the different growth conditions (Fig. 25). This increase of Uchl1 mRNA 
association to heavier polysomes upon rapamycin treatment did not occur in cells 
overexpressing the dominant-negative form of antisense Uchl1 (Fig. 25). Rack1 
transcript distribution was also studied as representative of TOP mRNAs which 
translation is specifically suppressed by rapamycin (Jefferies et al., 1997). As 
expected, Rack-1 mRNA was mostly associated with polysomes in growing cells 
(DMSO), but shifted to subpolysomal particles after rapamycin treatment (Fig. 25). 
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AS Uchl1 Identifies a New Functional Class of Long Noncoding Antisense RNAs. 
The collection of FANTOM3 non-coding cDNAs was bioinformatically screened for 
clones representing natural antisense transcript 5’ head to head overlapping to protein 
coding genes. This list was subsequently analyzed for the presence of embedded 
SINEB2 of the B3 types in reverse complement orientation in the 3’ half of AS RNA. 
31 transcripts and S/AS pairs were thus identified (Table 2).  
 
Table 2. Family of FANTOM3 non-coding RNA clones that are antisense to protein coding genes and 
contain embedded SINEB2 in inverted orientation. In red, S/AS pairs tested. 
 
 
On the bases of the expression of their protein coding mRNA counterpart in MN9D 
dopaminergic cells (Biagioli et al., 2009), an antisense RNA (Rik4833404H03 – 
GeneBank AK029359.1) to the Ubiquitously eXpressed Transcript (Uxt, 
NM_013840) was then chosen (Fig. 26) and tested for its ability to induce 
upregulation of the sense protein coding overlapping gene. Transfection of antisense 
Uxt (AS Uxt) in MN9D dopaminergic cell shows transient upregulation of Uxt 
protein product with no change in the total mRNA levels (Fig. 26) indicating that AS 
Uxt was able to increase protein levels post-transcriptionally likewise AS Uchl1. 
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a  
b        
Figure 26. Natural antisense lncRNAs increases target protein level. a, Scheme of Uxt/antisense 
Uxt genomic organization. b, Antisense Uxt increases endogenous UXT protein levels (left; units for 
numbers along the left of gels indicate kDa) without affecting RNA levels (right) in transfected MN9D 
cells. Data indicate mean ± s.d., n ≥ 3. 
 
 
 
Synthetic Antisense lncRNAs Increase Target Protein Levels. 
With the series of deletion mutants so far tested two likely functional domains were 
identified in AS Uchl1 transcript: the 5’end region overlapping Uchl1 mRNA and the 
inverted SINEB2 sequence along the 3’ tail. In order to take advantage of the 
enhancement of translation due to the SINEB2 repeat but driven by the 5’ 
overlapping region we obtained an artificial construct subcloning the 73 bp 
overlapping (OL) sequence to Uchl1 mRNA immediately close to the repetitive 
elements in Δ5’ AS Uchl1 which lacks the first exon of full length AS Uchl1 and 
therefore the overlap to its sense RNA. This shorter version of AS Uchl1 was named 
AS Uchl1-73bp (Fig. 27). Nevertheless the lacking of more than 300 bp from the first 
exon of AS Uchl1, AS Uchl1-73bp increased UCHL1 levels as much as the full-
length clone (Fig. 27). 
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a  
b     c    
Figure 27. Synthetic short AS Uchl1 is able to increase UCHL1. a, Scheme of mutant and scramble 
control in 5’ to 3’ orientation. b, A 73 bp overlap (OL) of AS Uchl1 is sufficient to increase UCHL1 in 
transfected HEK cells. Units for numbers along the left of gels indicate kDa. c, qRT-PCR from 
transfected HEK cells with AS Uchl1-73bp. Relative abundance of endogenous Uchl1 mRNA and 
over-expressed deletion mutants are shown. Antisense scramble (AS SCR) and full length AS Uchl1 
(FL) were used as negative and positive controls, respectively. Data indicate mean ± s.d., n ≥ 3. 
 
 
 
Of the two functional domains identified in AS Uchl1 the SINEB2 repetitive element 
conferred the protein synthesis activation domain whereas the 5’ region likely 
provided the specificity for the sense target gene. To further investigate the combined 
activity of an OL region and the SINEB2 sequence from AS Uchl1 a chimerical AS 
RNA was obtained by swapping the 5’end OL with a sequence antisense to an mRNA 
of choice. We thus synthesized a 72 nucleotide-long artificial sequence antisense to 
the AUG-containing region as transcribed from pEGFP, and inserted it into Δ5’ AS 
Uchl1 to generate antisense GFP (AS GFP) (Fig. 28a). 
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a    
b     
Figure 28. Synthetic antisense lncRNA increases target protein levels. a, Scheme of antisense GFP 
construct. Δ5’AS Uchl1 with repetitive elements (SINEB2, blue  Alu, red) and overlap (green) regions 
are indicated. b, Inverted SINEB2 plus the overlap sequence increase GFP levels in transfected HEK 
cells (left, units for numbers along the left of gels indicate kDa) without affecting its transcription 
(right). Data indicate mean ± s.d., n ≥ 3. 
 
 
 
Co-transfection of AS GFP with pEGFP strongly increased GFP protein but not GFP 
mRNA levels in HEK cells (Fig. 28b). Moreover when we pulsed cells with 
radioactive methionine and immunoprecipitated GFP, AS GFP expression induced an 
increase in radioactively labelled, neo-synthesized GFP, without affecting mRNA 
levels (Fig. 29). Taken together, these results demonstrated that the antisense RNA 
enhancement of translation was redirected through the replacement of its 5’ 
overlapping region. 
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a   b  c  
Figure 29. AS GFP enhances GFP de novo synthesis. HEK cells were transfected with pEGFP 
plasmid and control vector (-) or AS GFP; 24 hours after transfection cells were pulse-labeled with 
[
35
S]-Methionine/Cysteine for 1 hour. Labeled cells were lysed and immunoprecipitated with anti-GFP 
antibody. An aliquote of protein extract was used to monitor inputs. a, Autoradiography of IP and 
input. Bands of translated GFP were quantified relative to inputs. b, Expression of transfected 
constructs was analyzed in the same cells by western blotting to detect GFP protein (β-Actin served as 
a loading control, units for numbers along the left of gels indicate kDa). c, qRT-PCR to detect GFP and 
AS GFP transcripts. Expression was normalized to β-Actin and mRNA levels in cells transfected with 
GFP plus empty vector was set to 1. 
 
 
 
Uncoupled In Vitro Transcription and Translation for GFP S/AS Pair. 
In order to develop a high-throughput assay to test more chimerical AS RNAs we set 
up an uncoupled in vitro transcription and translation procedure taking advantage of 
commercially available lysates and extracts. Clones for GFP, AS GFP, and AS SCR 
as negative control were linearized at the 3’end of vector multiple cloning site and in 
vitro transcribed by T7 RNA polymerase. After DNase treatment RNAs were 
purified, quantified, and loaded onto denaturing formaldehyde agarose gel (Fig. 30). 
Different quantities and combinations of sense (S) and antisense (AS) RNAs were 
then added directly to translation-competent lysates. After the in vitro translation 
reaction samples were analyzed by western blotting with antibody against GFP. All 
lysates were tested for competence of GFP translation alone (Fig. 30). The wheat 
germ system proved to be the most efficient lysate since as few as 5 μl of extract were 
sufficient for producing GFP protein at detectable levels. 
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a           b  
Figure 30. Control of uncoupled in vitro transcription and translation assay. a, In vitro transcribed 
RNAs loaded onto denaturing formaldehyde 1% agarose gel; expected size for GFP transcript is 0.75 
Kbp and 1.2 Kbp for AS GFP and AS SCR. b, Lysates for in vitro translation are tested for GFP 
translation, Rabbit Reticulocyte Lysate (RRL), Insect Cell Extract (ICE), Wheat Germ Extract (WGE). 
 
 
 
15 μl of rabbit reticulocyte lysate were used in every in vitro translation reaction. To 
test the assay several quantities of sense GFP RNA were tested together with 
increasing quantities of antisense GFP RNA. The highest GFP protein induction was 
achieved with S/AS RNA ratio of 1:3. In rabbit reticulocyte system we detected an 
average enhancement of GFP translation of 1.7 fold (n ≥ 10) when AS GFP RNA was 
added to GFP mRNA (Fig. 31). For insect cell extract the reactions were also 
performed with 15 μl of lysate.  eeping the S/AS RNA ratio to 1:3 we obtained an 
average induction of GFP protein translation of 1.7 fold (n ≥ 3) when AS GFP RNA 
was added together with GFP mRNA (Fig. 31). Performing the same experiment in 
wheat germ extract we reported an induction of GFP protein production of 2.1 fold 
(n≥ 8) in presence of AS GFP RNA (Fig. 31). These data indicated that the 
mechanism underneath AS GFP translation enhancement is evolutionary conserved in 
three very different organisms, such as rabbit, insect and wheat. 
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a      
 
b c     
Figure 31. In vitro translation of GFP S/AS pair in different lysates. a, In vitro translation in rabbit 
reticulocyte lysate with two quantities of S RNA and two S/AS RNA ratios for one of them. b, In vitro 
translation in insect cell extract with two S/AS RNA ratios. c, Example of in vitro translation in wheat 
germ extract with S/AS RNA ratio of 1:3. For a, b, and c GFP was quantified by ImageJ and AS SCR 
control samples were set to 1. 
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DISCUSSION 
Initially classified as “transcriptional noise” long noncoding RNAs (lncRNAs) are 
today defined as RNA genes able to orchestrate genetic regulatory outputs (Rinn and 
Chang, 2012). The renewed interest in RNA biology is particularly focused on the 
central nervous system where neural cells are highly transcriptionally active and 
exhibit robust expression of lncRNAs (Gustincich et al., 2006). In fact, in the central 
nervous system lncRNAs show precise patterns of expression in terms of time and 
regional, cellular, or subcellular localization and these dynamics mediate several 
nervous system processes and neurological disease states. 
In the broad class of lncRNAs, antisense RNAs (AS RNA) represent a powerful 
subclass for one main reason: AS RNAs contain both the information necessary for 
target recognition, which is the overlapping sequence with protein coding transcript, 
and additional analogical or digital features for interaction with RNA binding proteins 
and/or co-factors. AS RNAs can thus be the perfect candidate for post-transcriptional 
regulation of gene expression. 
Here we report a novel function for a SINEB2 repeat embedded in an antisense 
lncRNAs AS Uchl1, specifically expressed and enriched in the nucleus of mouse 
dopaminergic cells. AS Uchl1 is involved in the post-transcriptional control of gene 
expression of its sense mRNA Uchl1 through the SINEB2 repetitive element 
embedded in its sequence. Furthermore, we showed how this natural antisense 
noncoding transcript was successfully modified to obtain a chimerical lncRNA 
antisense to GFP. In conclusion we proposed an in vitro translation assay as possible 
high throughput screening for future artificial AS lncRNAs as inducer of translation. 
 
AS Uchl1 as Stress-Responding LncRNA. 
Previous experiments indicated that AS Uchl1 overexpression was able to drive 
Uchl1 protein upregulation with a post-transcriptional mechanism. Moreover, 
rapamycin treatment of mouse dopaminergic cells induced a similar upregulation of 
Uchl1 protein only in the presence of AS Uchl1 shuffling from nucleus to cytoplasm. 
These findings are consistent with the idea that acute stress response does not 
increase production of new transcripts, but affects the post-transcriptional regulation 
of previously synthesized mRNAs that already compose the cytoplasmic cohort. To 
further investigate the effect of cytoplasmic AS Uchl1 on Uchl1 translation we 
analyzed the polysomal profile of rapamycin-treated cells by two different technical 
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approaches, qRT-PCR and northern blotting. Both experiments showed an increased 
association of Uchl1 mRNA to heavy polysomes upon rapamycin treatment and 
confirmed the involvement of protein translation in AS Uchl1 function. 
Rapamycin impairs Cap-dependent initiation of translation by blocking mTORC1 
kinase. The same arrest occurs upon stress, when Cap-dependent translation of most 
proteins is greatly reduced and the expression of a small group of proteins, such as 
heat shock and pro-survival proteins, is enhanced. How the translation of certain 
mRNAs is temporarily halted and simultaneously increased for another subset of 
proteins is still not clear. Proposed mechanisms take into account two well known 
viral strategies, Internal Ribosome Entry Site or IRES (Jang et al., 1988; Pelletier et 
al., 1988) and ribosome shunting (Fütterer et al., 1993). Both strategies overcome 
host translation through the direct translocation of the ribosome from the upstream 
initiation complex to the start codon without the need for eIF4A helices activity to 
unwind RNA secondary structures. Indeed, IRES-mediated translation is prominent in 
conditions of stress, for instance Endoplasmic Reticulum (ER) stress, hypoxia, 
nutrient limitation, mitosis and cell differentiation (Komar and Hatzoglou, 2011). 
In D. melanogaster models of PD rapamycin suppressed the pathological phenotype 
by promoting the activation of 4E-BP (Tain et al., 2009). In mice rapamycin shows 
both in vitro and in vivo protection for dopaminergic neurons upon neurochemical 
intoxication (Malagelada et al., 2010) and alleviates L-DOPA induced diskynesia in 
humans (Santini et al., 2009). The protective effect exerted by rapamycin on neurons 
has been explained by both induction of autophagy (Sarkar et al., 2009; Dehay et al., 
2010) and suppression of RTP801 translation (Malagelada et al., 2006). 
According to our data after rapamycin treatment of mouse dopaminergic cells AS 
Uchl1 re-localize into the cytoplasm and rescues Uchl1 from occurring block of 
translation. Moreover, the expression of full length AS Uchl1 is required for 
rapamycin-induction of UCHL1. In particular, the inverted SINEB2 element 
embedded in AS Uchl1 transcript has a crucial role in this stress-induced response. 
Interestingly, Uchl1 is a pro-survival protein for neurons and for this reason the 
manipulation of its expression has been proposed for intervention in 
neurodegenerative diseases, including PD and AD. We propose that the antisense-
driven elevation of Uchl1 protein in dopaminergic cells occurring upon rapamycin 
might be an additional molecular event to explain the neuroprotective property of this 
drug. 
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A New Class of LncRNAs. 
The mechanism proposed for AS Uchl1 suggests the intriguing hypothesis that it 
might exist a pool of cellular nuclear-retained RNAs, normally kept latent in the 
nucleus, that are ready to respond to acute stimuli by changing their subcellular 
location. We already know that stress-dependent nuclear-cytoplasm shuttling of 
lncRNAs seems to be a common strategy to regulate translation since CTN-RNA, 
another nuclear-retained lncRNA, unveiled a cryptic protein coding sequence at its 
3’end when in the cytoplasm (Prasanth et al., 2005). By changing location, RNA 
molecules can be able to exert their specific function, i.e. for AS Uchl1 using the 
SINEB2 module to increase protein translation and the 5’ overlap to target the sense 
mRNA. We thus clustered several antisense transcripts that are overlapping 5’ head-
to-head to RefSeq genes in mouse and have a SINEB2 element in reverse 
complement within their sequence. From this list we experimentally found that a 
second antisense RNA (AS Uxt) is able to drive protein upregulation of its protein-
coding overlapping partner. These results suggest that AS Uchl1 and AS Uxt may be 
a representative member of a new functional class of lncRNAs which are part of S/AS 
pairs in the mammalian genome. They require a 5’ end overlap to their sense 
counterpart and a SINEB2 repeat along their 3’ tail. The region at the 5’ provides 
specificity to a protein-coding mRNA partner transcribed from the complementary 
strand, while the inverted SINEB2 element is required for translational activation. 
It will be interesting in the future to capture all the transcripts that contain a reverse 
complement SINEB2 element via Deep Sequencing of 5’RACE products obtained 
from SINEB2 internal primer, thus profiling all the cellular pool of non-coding RNAs 
that can use this SINEB2 module to enhance translation. It is also reasonable that all 
the ncRNA molecules capable to reprogram translation of cognate protein-coding 
mRNAs via a SINEB2 module may represent potential pharmacological targets, 
together with involved protein interactors still to identify. 
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AS LncRNAs as Therapeutic Tool 
Besides the role that ncRNAs have in several biological systems, they have emerged 
as particularly relevant players in a sophisticated place like the CNS, where the major 
diversity of ncRNAs is found (Mercer et al., 2008). LncRNAs generally play a role 
by modulating transcription, post-transcriptional processing, and translation of 
mRNAs. 
In the central nervous system they play additional roles in mediating nervous system 
development, homeostasis, stress responses and plasticity (Qureshi et al., 2010). 
Moreover, lncRNAs are involved in the pathophysiology of a spectrum of CNS 
pathologies including neurodevelopmental, neurodegenerative, neuro-oncological and 
psychiatric diseases. 
LncRNAs are implicated in the pathophysiology of neurodevelopmental disorders 
associated with genomic imprinting, such as Prader–Willi syndrome (PWS) and 
Angelman syndrome (AS) (Koerner et al., 2009). 
As an example of neurodegenerative disorder, deregulation of lncRNAs has been 
assessed for AD, where the levels of lncRNA AS BACE1 are correlated with higher 
BACE1 protein which, in turn, leads to increased production of Aβ peptide (Faghihi 
et al., 2008). Another study utilized human AD brain tissue to link alterations in 
levels of lncRNA BC200 with AD pathogenesis. Increased levels of BC200 were 
found in brain regions that are preferentially affected in AD (Mus et al., 2007). 
Moreover lncRNAs are known targets of the master epigenetic regulator REST/NRSF 
(repressor element-1 silencing transcription factor/neuron-restrictive silencing factor) 
in both mouse and human (Johnson et al., 2009). Deregulation of REST and CoREST 
functions is linked to a range of central nervous system pathologies that include 
cancer (glioblastoma, medulloblastoma, and neuroblastoma), neurodegenerative 
disease (Huntington's disease), neurodevelopmental disorder (Down syndromeand X-
linked mental retardation), epilepsy, and ischemia (Qureshi and Mehler, 2009). 
Neurological disorders like epileptogenesis involve BC1/BC200 brain-specific 
lncRNAs and Evf2, since they modulate neural network plasticity and excitability 
(Mercer et al., 2008; Qureshi et al., 2010). 
In addition to neurological diseases, a number of psychiatric disorders have also been 
associated with lncRNAs. For example, the disruption of the DISC sense/antisense 
genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 
lncRNA, has been linked to the risk of developing schizophrenia, schizoaffective 
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disorder, bipolar disorder, major depression, and autistic spectrum disorders (Chubb 
et al., 2008; Williams et al., 2009). 
The discovery of new noncoding molecules and their function in the brain can 
constitute a starting point for the development of novel diagnostic and/or therapeutic 
approaches directed for example, to those lncRNAs whose downregulation or 
overexpression is aberrant in central nervous system disorders. 
Historically, it has been easier to identify drug compounds and research tools that 
inhibit or downregulate a drug target than to identify agents that are capable of 
inducing its activation or upregulation. In fact, the majority of currently available 
drugs exhibit an inhibitory mechanism of action and there is a relative lack of 
pharmaceutical agents that are capable of increasing the activity of single effectors or 
pathways. Indeed, the upregulation of many genes, including tumour suppressors, 
growth factors, transcription factors and genes that are deficient in various genetic 
diseases would be desired in specific situations. For instance, in the case of 
neurodegenerative disorders their progression, at least when they are treated relatively 
early, could conceivably be alleviated by boosting the activities of neuroprotective 
growth factors. 
Current strategies to upregulate specific therapeutic targets include nuclear receptor 
ligands, chromatin modulators, enzyme replacement, artificial transcription factors, 
and miRNA modulators. Although these strategies are promising, none of them can 
afford the upregulation of endogenous genes in a locus-specific manner. 
However, by targeting a regulatory ncRNA it may be possible to upregulate an 
endogenous gene in a natural fashion. This may, for example, be relevant to diseases 
arising as a result of haploinsufficiency, in which patients have only one functional 
copy of a given gene owing to mutations, or in cases where both copies are less active 
than normal. As such, identifying and inhibiting ncRNAs that can regulate the 
expression of such genes may lead to enhanced activation of at least one functional 
copy and restoration of the normal cell phenotype. 
Finally, a possible advantage of targeting lncRNAs is their relatively low abundance 
compared to mRNAs. Indeed, if these lncRNAs are transcriptional regulators, a small 
number of copies may suffice to show efficacy. Therefore, lncRNA inhibitors could 
potentially be administered at a lower dose than a conventional oligonucleotide used 
for mRNA knockdown. 
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Of particular importance is the observation that the inhibition of many antisense 
transcripts can derepress and therefore elevate levels of the sense transcript partner 
(known as discordant regulation) or, less often, decrease the expression of the sense 
transcript (known as concordant regulation) (Wahlestedt, 2006; Faghihi et al., 2010). 
In the case of the lncRNA we report here, the antisense noncoding transcript is not a 
real target for PD therapy but it could be a drug tool itself. In fact, through an increase 
of AS Uchl1 expression the level of Uchl1 protein could be restored in dopaminergic 
cells of PD patients. One of the main advantages in upregulating an endogenous gene 
in a locus-specific manner, as in AS Uchl1 example, is the reduction of off-target 
effects. 
Concerns remain for the delivery of a therapeutic RNA transcript, especially as the 
central nervous system is involved. Achieving safe and efficient in vivo delivery 
remains a crucial hurdle and several strategies to overcome such hurdles are currently 
being investigated, including various delivery approaches: for example, the use of 
viral vectors such as adenoviruses and retroviruses, as well as non-viral vectors such 
as polyplexes, lipoplexes and peptide- or protein-based systems (Bennett and Swayze, 
2010). 
 
 
 
Repetitive Elements 
Despite the higher number of insertions, repetitive elements are not evenly distributed 
throughout the genome. For instance, inverted Alu elements in close proximity to 
each other are less frequently identified in the human genome than Alu insertions in 
the same orientation (Stenger et al., 2001) and this can only partially be attributed to 
insertional bias of insertions in the same orientation (Chen et al., 2008). Indeed, 
inverted repeats likely represent hotspots of genomic instability, as seen in studies 
with yeast (Lobachev et al., 2000). Inverted Alu elements that are closely spaced 
appear to build hairpin structures, which can cause Double Strand Breaks (DSBs) of 
the DNA and excision of inverted Alu elements from the human genome. Moreover, 
hairpin structures involving Alu elements appear to cause replication stalling and 
collapse of the replication fork, which can lead to DSBs and/or intra- or 
intermolecular template switch (Voineagu et al., 2008). 
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In this study we report a new function for an inverted SINEB2 element embedded in 
AS lncRNA transcripts, which also contain a 5’ region of overlap to the relative sense 
mRNA transcript. While the physical interaction between the transcripts of Uchl1 
S/AS pair is a speculation for now, the mechanism underlying AS Uchl1 
enhancement of Uchl1 translation is still unknown. Deletion mutants affecting 
internal domains of the SINEB2 element, such as the A and B boxes of the internal 
promoter for RNA pol III, could further restrict the length of the functional domain of 
AS Uchl1. 
The upregulation of Uchl1 protein involves an initial shuffling of AS Uchl1 from 
nucleus to cytoplasm and a following shift of Uchl1 mRNA to highly translating 
polysomes. This latter passage depends on the inverted SINEB2 repeat present along 
AS Uchl1 sequence. Next step in order to get a hint of the implicated cellular 
pathways would be the identification of proteins interacting with AS Uchl1 and in 
particular with the SINEB2 sequence. 
Even though lncRNAs exhibited poor sequence conservation across species (Taft et 
al., 2007), RNA structure is arguably more highly conserved than its sequence 
(Mathews et al., 2010), which indicates that conventional sequence alignment across 
species may not reveal functionally conserved RNA motifs. SINE elements have a 
highly conserved secondary structure that derives from the RNA molecule from 
which they emerged (tRNA for mouse SINEB2 repeats) and is likely conserved when 
embedded in larger transcripts. The study of the three-dimensional structure of AS 
Uchl1 SINEB2 element and structure-function analysis could further help to elucidate 
the physical interactions of this functional domain with cellular proteins. 
 
 
 
In Vitro Translation Assay of Artificial AS LncRNAs. 
We demonstrated how AS Uchl1 function could be redirect and exploited for 
inducing the translation of a target protein, such as GFP, in cells through the 
replacement of its 5’ overlapping region. Here, we propose an uncoupled in vitro 
transcription and translation assay as initial screening for functional chimerical AS 
lncRNAs designed according to AS Uchl1 functional domains and sequence. All 
three tested commercially available lysates for in vitro translation (rabbit reticulocyte 
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lysate, insect cell extract, and wheat germ) were able to recapitulate the enhancement 
of protein synthesis driven by AS GFP in cells. 
In particular, the wheat germ extract showed the highest efficiency of translation 
considering the low amount of extract sufficient to produce GFP at detectable levels. 
Since we are interested in observing a translational upregulation alone, the choice of 
one lysate over the others is not dictated by the need to eventually produce a 
functional protein. As far as the enhancement of translation is conserved among 
lysates which are obtained from different organisms, intrinsic differences in post-
translation modifications are not relevant. 
Indeed, a lot of questions remain open concerning the mechanism of translation 
induction of this newly identified class of AS lncRNAs. The identification of the 
protein interactors to AS Uchl1 transcript and its inverted SINEB2 element could be a 
valuable starting point for further experimental hypothesis. Then, the generalization 
of a mechanism of translation enhancement has to take into account the complexity of 
a cell and adapt to the variety of its proteome. 
In conclusion, the in vitro translation protocol could be a useful and rapid assay to 
screen for functional AS GFP deletion mutants, but its technical potential as high 
throughput screening of AS lncRNAs as enhancer of translation needs further 
experimental trials. 
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Long non-coding antisense RNA controls Uchl1
translation through an embedded SINEB2 repeat
Claudia Carrieri1*, Laura Cimatti1*, Marta Biagioli1,2, Anne Beugnet3, Silvia Zucchelli1,2, Stefania Fedele1, Elisa Pesce3,
Isidre Ferrer4, Licio Collavin5,6, Claudio Santoro7, Alistair R. R. Forrest8, Piero Carninci8, Stefano Biffo3,9, Elia Stupka10
& Stefano Gustincich1,2
Most of the mammalian genome is transcribed1–3. This generates a
vast repertoire of transcripts that includesprotein-codingmessenger
RNAs, long non-coding RNAs (lncRNAs) and repetitive sequences,
such as SINEs (short interspersed nuclear elements). A large per-
centage of ncRNAs are nuclear-enriched with unknown function4.
Antisense lncRNAs may form sense–antisense pairs by pairing with
a protein-coding gene on the opposite strand to regulate epigenetic
silencing, transcription and mRNA stability5–10. Here we identify a
nuclear-enriched lncRNA antisense to mouse ubiquitin carboxy-
terminal hydrolase L1 (Uchl1), a gene involved in brain function
andneurodegenerativediseases11.AntisenseUchl1 increasesUCHL1
protein synthesis at a post-transcriptional level, hereby identifying a
new functional class of lncRNAs. Antisense Uchl1 activity depends
on the presence of a 59 overlapping sequence and an embedded
inverted SINEB2 element. These features are sharedby other natural
antisense transcripts and can confer regulatory activity to an arti-
ficial antisense to green fluorescent protein. Antisense Uchl1 func-
tion is under the control of stress signalling pathways, as mTORC1
inhibition by rapamycin causes an increase inUCHL1protein that is
associated to the shuttling of antisenseUchl1RNA from the nucleus
to the cytoplasm. Antisense Uchl1 RNA is then required for the
association of the overlapping sense protein-codingmRNA to active
polysomes for translation. These data reveal another layer of gene
expression control at the post-transcriptional level.
To discover non-coding antisense transcripts of sense–antisense
(S–AS) pairs expressed in the brain, the mouse syntenic loci of genes
involved inneurodegenerative diseaseswere identified computationally
and examined in the Ensembl browser (http://www.ensembl.org). The
FANTOM2 clone 6430596G22 was classified as a spliced antisense
lncRNA of the Uchl1 gene11; we refer to this as antisense Uchl1. UCHL1
is a neuron-restricted protein that acts as a deubiquitinating enzyme,
ubiquitin ligase or monoubiquitin stabilizer12. An in-frame deletion in
theUchl1 gene, as in gracile axonal dystrophymice, leads to ataxia and
axonal degeneration. Although an association of UCHL1 gene muta-
tions to familial Parkinson’s disease has not been confirmed in inde-
pendent families, oxidative inactivation of UCHL1 protein has been
reported in Parkinson’s disease and Alzheimer’s disease brains13–15.
AntisenseUchl1 is a 59 head-to-head transcript that initiates within
the second intron of Uchl1 and overlaps the first 73 nucleotides of the
sense mRNA including the AUG codon. By 59 rapid amplification of
cDNA ends (RACE), the transcriptional start site (TSS) of antisense
Uchl1 was mapped to the second intron of Uchl1 (Fig. 1a). The non-
overlapping part of the transcript contains two embedded repetitive
sequences, SINEB1 of the F1 subclass (Alu) and SINEB2 of the B3
subclass, identified by Repeatmasker16–18. The FANTOM2 clone spans
a genomic region of 70 kilobases (kb) (Fig. 1a) and its genomic organi-
zation is conserved in mammals (Supplementary Fig. 1a).
Sense and antisense Uchl1 expression in mouse and human tissues
was similar (Fig. 1b andSupplementaryFig. 1b). In themouse, antisense
Uchl1 RNA was highly expressed in the ventral midbrain (Fig. 1b) and
in the MN9D dopaminergic cell line (data not shown). Mature Uchl1
mRNA was observed mainly in the cytoplasm of dopaminergic neu-
rons, whereas antisense Uchl1 was enriched in the nucleus (Fig. 1c and
Supplementary Fig. 2). Antisense Uchl1 expression was confirmed by
qRT–PCR from dopaminergic neurons purified with laser capture
microdissection (LCM, Supplementary Fig. 3).
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Figure 1 | Expressionof antisenseUchl1 in dopaminergicneurons. a,Uchl1/
antisense (AS)Uchl1 genomic organization.Uchl1 exons are in black; 39 and 59
UTRs are inwhite; antisenseUchl1 exons are grey; repetitive elements are in red
(Alu) and blue (SINEB2). Introns are indicated as lines. b, Quantitative
expression of Uchl1 and antisense Uchl1 in mouse tissues (DDCt/DDCtmax).
CER, cerebellum; CTX, cortex; OB, olfactory bulb; STR, striatum; VM, ventral
midbrain. c, AntisenseUchl1 (red) andUchl1 (green) transcripts are expressed
in the nucleus and cytoplasm of TH-positive dopaminergic neurons of the
substantia nigra (blue).
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Transient expression of antisense Uchl1 in MN9D cells caused no
significant change in endogenous Uchl1mRNA expression. Notably, a
strong and reproducible upregulation of UCHL1 protein was detected
within 24h (Fig. 2a).When increasing amounts of antisenseUchl1were
co-transfected withmurineUchl1 intoHEK cells, which do not express
either transcript, dose-dependent UCHL1 protein upregulation was
recorded in the absence of any significant change in the quantity of
exogenous Uchl1 mRNA (Fig. 2b). These data indicate that antisense
Uchl1 regulates UCHL1 expression at a post-transcriptional level.
AntisenseUchl1deletion constructs lacking the59 first exon (antisense
Uchl1(D59)) or the last three exons (antisense Uchl1(D39)) failed to
induce UCHL1 protein in MN9D and HEK cells, suggesting that both
59 and 39 components are important to antisense Uchl1 function
(Fig. 2c and Supplementary Fig. 4a). Targeted deletion of the region
containing the embedded SINEB2 and Alu repetitive sequences (DAS)
was also able to prevent UCHL1 protein induction. Deletion of each
repetitive element separately revealed that SINEB2 is the functional
unit required by antisense Uchl1 for increasing UCHL1 protein syn-
thesis (Fig. 2d). In all casesnochange inUchl1mRNAlevelwas detected
(Supplementary Fig. 4b).Amutantwith a flippedSINEB2 sequencewas
unable to increase UCHL1 protein levels, thus proving the orientation-
dependent activity of the SINEB2 domain embedded within antisense
Uchl1 (Fig. 2d). Importantly, an artificial construct containing the 73-
nucleotide overlapping sequence immediately close to the repetitive
elements in antisense Uchl1(D59) increased UCHL1 levels as much as
the full-length clone (Fig. 2e and Supplementary Fig. 4c).
We then considered whether other SINEB2-containing lncRNAs
may post-transcriptionally regulate the expression of their protein-
coding partner, on the basis of similar structural elements. The
FANTOM3 collection of non-coding cDNAs was bioinformatically
screened for natural antisense transcripts that contain SINEB2 ele-
ments of the B3 subclass in the correct orientation and 59 head-to-head
overlapping to a protein-coding gene. This identified 31 S–AS pairs
similar to the Uchl1/antisenseUchl1 structure (Supplementary Fig. 5).
By sequence alignment, we chose antisenseUxt (4833404H03), antisense
of ubiquitously expressed transcript (Uxt), as the one with the most
similar SINEB2 elements (Fig. 3a). Transfection of antisense Uxt in
MN9Dcells elicited an increase ofUXTprotein level with no change in
UxtmRNA (Fig. 3b), indicating that antisenseUxtwas similarly able to
increase protein levels post-transcriptionally.
These data indicate a model whereby lncRNAs regulate protein syn-
thesis through the combined activities of two domains. The 59 antisense
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Figure 2 | AntisenseUchl1 regulates UCHL1protein levels via an embedded
inverted SINEB2 element. a, Antisense Uchl1-transfected dopaminergic
MN9D cells show increased levels of endogenous UCHL1 protein, with
unchanged mRNA quantity. b, Increasing doses of transfected antisenseUchl1
titrate UCHL1 protein but not mRNA levels in HEK cells. Data in a and
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right panel) UCHL1 protein levels. Scheme of D59 or D39 deletion mutants is
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region provides specificity for the sense target gene whereas the repeti-
tive element confers the protein synthesis activation domain. Themodel
predicts that by swapping the overlapping sequence one may increase
the amount of proteins encoded by the mRNAs of choice acting at the
post-transcriptional level. We thus synthesized a 72-nucleotide-long
artificial sequence antisense to the AUG-containing region as trans-
cribed from pEGFP, and inserted it into antisense Uchl1(D59) to gen-
erate antisense GFP (Fig. 3c). Co-transfection of antisense GFP with
pEGFP strongly increased GFP protein but not mRNA levels in HEK
cells (Fig. 3d). When we pulsed cells with methionine for an hour and
immunoprecipitatedGFP, antisenseGFP induced an increase in radio-
actively labelled, neo-synthesized GFP, without affectingmRNA levels
(Supplementary Fig. 6).
To understand how the antisense Uchl1 transcript operates and the
physiological conditions in which it might act, we assayed several
stimuli and/or drugs for their ability to modulate UCHL1 protein
expression. Inhibition of mTORC1 signalling favoured an increase in
UCHL1 levels in a range from 1.5- to 2.5-fold (Fig. 4a). This effect was
evident with as low as 20 nM rapamycin (Supplementary Fig. 7) and
was concomitant with dephosphorylation of mTOR targets p70S6K
and 4E-BP1. Furthermore, the effect was not due to a stabilization
of the protein, as co-application of cycloheximide decreased UCHL1
protein levels (Supplementary Fig. 8a). These data are surprising
because rapamycin impairs formation of the CAP-dependent com-
plex and hence translation of highly structured mRNAs19. However,
in agreement with previous reports, in our experimental settings
mTORC1 inhibition only slightly impairs the global rate of translation
(Supplementary Fig. 8b). Under these conditions, it has been proposed
that rapamycin may affect competition among different mRNAs20. If
so, we proposed that inhibition of the CAP complex formation favours
the translation of Uchl1 mRNA with a mechanism that requires anti-
sense Uchl1.
To test thismodel, we used two complementary approaches to estab-
lish a loss-of-function phenotype. First, we downregulated antisense
Uchl1 levels with short hairpin RNA (shRNA) targeting its promoter
region.MN9Dcells constitutively expressing shRNA for antisenseUchl1
did not show any changes in UCHL1 protein levels upon rapamycin
treatment, whereas scramble control cells showedUCHL1 upregulation
as in the parental line (Fig. 4b). Dephosphorylation of p70S6K and 4E-
BP1 proved that rapamycin inhibited mTOR activity as expected. We
then exploited the dominant-negative property of an antisense Uchl1
mutant lacking the SINEB2 repeat element. Overexpression of anti-
sense Uchl1(DSINEB2) inhibited the ability of full-length antisense
Uchl1 to increase protein levels (Supplementary Fig. 9). Upon rapa-
mycin treatment, cells stably expressing antisense Uchl1(DSINEB2)
did not show any UCHL1 protein induction despite dephosphoryla-
tion of mTOR targets (Fig. 4c). These complementary experiments
prove that functional antisense expression is required for UCHL1
protein increase elicited by rapamycin.
Because antisense Uchl1 transcript is enriched in the nucleus of
dopaminergic neurons, we measured antisense Uchl1 and Uchl1 RNA
content in the nucleus and cytoplasm of MN9D cells upon rapamycin
treatment. As shown in Fig. 4d, rapamycin substantially increased anti-
sense Uchl1 concentration in the cytoplasmic fraction. This effect was
confirmed by a concomitant decrease in its nuclear steady-state levels,
and by the absence of any de novo transcription. The total content of
primary and spliced transcripts remained constant (data not shown).
Uchl1 mRNA showed no change in subcellular distribution, de novo
transcription or total cellular content. These data demonstrate that
antisense Uchl1 localization can be regulated by the mTOR pathway,
and its cytoplasmic level correlates with the expression of UCHL1
protein.
We therefore monitored the association ofUchl1mRNAwith poly-
somes to assess the role of translation in antisense Uchl1-mediated
UCHL1 protein induction. Fractionated MN9D cell extracts were
used to measure the recruitment of Uchl1 mRNA on polysomes by
qRT–PCR and northern blotting (Fig. 4e and Supplementary Fig. 10).
In basal conditions, Uchl1 mRNA was associated with translating
ribosomes. Rapamycin treatment induced a shift of Uchl1 mRNA to
heavier polysomes, consistent with an enhanced rate of translation
initiation; this increase of Uchl1 mRNA association to heavier poly-
somes did not occur in cells overexpressing the dominant-negative
form of antisense Uchl1 (Supplementary Fig. 11).
Antisense Uchl1 is the representative member of a new functional
class of lncRNAs that are part of S–ASpairs in themammalian genome
that require overlap at the 59 end and the action of a SINEB2 repeat.
This new function for SINEB2 sequences in the cytoplasm adds to their
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well-established role in the nucleus as inhibitors of RNA polymerase
II16. Stress-dependent nucleocytoplasmic shuttling of lncRNAsmay be
a common strategy to regulate translation, as CTN-RNA, another
nuclear-retained lncRNA, was found to have a cryptic protein-coding
sequence at its 39 end when in the cytoplasm21.
It is intriguing that this nuclear lncRNA-mediated mechanism for
post-transcriptional control of gene expression is active when CAP-
dependent translation is inhibited by rapamycin. This drug blocks
mTORC1 kinase, which activates the eIF4F complex19,22. However,
somemRNAs escapemTORC1 inhibition by being able to be recruited
to ribosomes in an eIF4F-independentmanner for presenting complex
mRNA loops that function as internal ribosomal entry sites (IRES)23.
Indeed, IRES-mediated translation is prominent in conditions of stress
or growth factor inhibition and its alteration affects processes such as
tumorigenesis22,24. In genetic and neurochemicalmodels of Parkinson’s
disease, mTORC1 inhibition protects dopaminergic neurons from
apoptosis25,26.
Antisense lncRNA-mediated translationmaybe anothermechanism
tomaintain synthesis of pro-survival proteins, such as UCHL1, that are
involved in rapamycin neuroprotective function and more generally in
cellular response to stress. Thismechanismmay represent the outcome
of an evolutionary pressure on the genomic organization of anti-stress
elements to favour gene-specific regulation of translation when CAP-
dependent initiation is reduced. Finally, natural and synthetic antisense
transcriptswith embedded repetitive elementsmay representmolecular
tools to increase translation of selected mRNAs, defining a potential
new class of RNA therapeutics.
METHODS SUMMARY
59 RACE for antisense Uchl1 was performed with Gene Racer (Invitrogen).
Double-fluorescence in situ hybridization of biotin- and digoxigenin-labelled
probes was detected using fluorochrome-conjugated reagents. Images were cap-
turedwithConfocal LaserMicroscopy (LEICA). Expression of antisenseUchl1was
performed on neuronal cells lines and dopaminergic neurons purified with LCM
from TH-GFP mice. Cell lines were cultured under standard conditions. shRNA
targeting the promoter of antisense Uchl1 was cloned in pSUPERIOR.Neo.GFP
vector (Oligo Engine). Polysomes were prepared by sucrose gradient and asso-
ciated Uchl1mRNA was measured by qRT–PCR and northern blotting.
Full Methods and any associated references are available in the online version of
the paper.
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METHODS
Oligonucleotides. The complete list of oligonucleotides used for cloning and for
quantitative real-time PCR experiments is included in Supplementary Information
(Supplementary Fig. 12).
Plasmids. Full-length DNA sequence of antisense Uchl1 was amplified via fusion
PCR starting from RACE fragment and FANTOM clone 6430596G22 (GenBank
AK078321.1)with forwardmouse antisenseUchl1FL and reversemouse antisense
Uchl1 FL primers.
Mouse Uchl1 mRNA was subcloned from FANTOM clone 2900059O22
(GenBank AK013729.1) in the unique PmeI site of pcDNA3.1.
cDNA sequence of human antisense UCHL1 was amplified from a sample of
human brain total RNA (Clontech, 636530) with the primers human 59F and
human 39R.
Oligonucleotides that target the sequence214/13 around the TSS of antisense
Uchl1were annealed and cloned into pSUPERIOR.Neo.GFP vector (OligoEngine)
in the BglII/XhoI site. Scrambled sequence was also cloned and used as control.
The antisense Uchl1 59 deletion mutant (D59) was generated by PCR using the
oligonucleotides forward mouse antisense Uchl1(D59) and reverse mouse anti-
sense Uchl1 FL. PCR fragment was cloned in the unique EcoRI site in pcDNA3.1.
The antisense Uchl1 39 deletion mutant (D39) was generated by PCR using the
forwardmouse antisenseUchl1FLand reversemouse antisenseUchl1(D39) primers
and cloned in the unique EcoRI site in pcDNA3.1.
The antisense Uchl1(DAS) (DAlu1 SINEB2) mutant was obtained by sub-
sequent cloning of PCR fragment I (NheI–EcoRI site) and PCR fragment II
(EcoRI–HindIII site) into pcDNA3.1. Primers forward mouse antisense Uchl1
FL Nhe and reverse pre-SINE B2 EcoRI were used to generate fragment I; primers
forward post-ALU EcoRI and reverse mouse antisense FL HindIII were used for
PCR fragment II.
The antisense Uchl1(DA) (DAlu, 1000–1045) mutant was generated with a
similar strategy to antisense Uchl1(DAS). Forward mouse antisense Uchl1 FL
NheI and reverse pre-ALU EcoRI were used for PCR fragment I; forward post-
ALU and reverse mouse antisense FL HindIII for PCR fragment II.
The antisense Uchl1(DS) (DSINEB2, 764–934) mutant was obtained with a
similar strategy to antisense Uchl1(DAS). Oligonucleotides forward mouse AS
Uchl1 FL NheI and reverse pre-SINE B2 EcoRI for fragment I; forward post-
SINE B2 EcoRI and reverse mouse AS FL HindIII for fragment II.
For antisenseUchl1(ASf) (Alu1 SINEB2 flipped), PCR fragment obtainedwith
the primers forward SINEB2 inside and reverse Alu flip was cloned in the unique
EcoRI site of antisense Uchl1(DAS).
For antisenseUchl1(Sf) (SINEB2 flipped), PCR fragment obtainedwith forward
SINE B2 inside and reverse SINE flip oligonucleotides was cloned in the unique
EcoRI site of antisense Uchl1 DSINEB2.
For antisense Uchl1(73 bp), the method of ‘annealing and primer extension’ of
two 39-end overlapping oligonucleotides was used to generate the 73-bp antisense
Uchl1 overlap region. Annealed fragment was obtainedwith antisenseUchl1 73 bp
forward and antisenseUchl1 73 bp reverse. Fragment was digested with XhoI and
EcoRV and ligated into antisense Uchl1 D59 plasmid.
The antisense SCR 73-bp mutant was obtained with a similar strategy as anti-
senseUchl1(73 bp). The annealing extension was performedwith oligonucleotides
with scramble (SCR) sequence (antisense SCR forward andantisense SCR reverse).
Full-lengthmouse antisenseUxtwas amplified by PCR starting fromFANTOM
clone 4833404H03 (GenBank AK029359.1) with specific primers (forwardmouse
antisenseUxt and reversemouse antisenseUxt). PCR fragmentwas subcloned into
pcDNA3.1 using XbaI and HindIII restriction enzymes.
The antisense GFP plasmid was generated with a similar strategy as antisense
Uchl1(73 bp). Seventy-two base pairs corresponding to nucleotide240/132 with
respect to the ATG of GFP sequence in pEGFP-C2 vector (Clontech) were chosen
as target sequence for artificial antisense DNA generation. For annealing, the GFP
antisense forward and GFP antisense reverse primers were used.
Cells.MN9Dcellswere obtained fromM. J. Zigmond.Cellswere seeded in100-mm
dishes in Dulbecco’s modified Eagle’s (DMEM) medium containing 10% fetal
bovine serum (Invitrogen) supplemented with penicillin (50 unitsml21) and strep-
tomycin (50 unitsml21). For experiments, cellswere plated inpoly-L-lysine (P2636,
Sigma) coated dishes and grown overnight. Approximately 50% confluent cells
were treated with 1mM rapamycin (R0395, Sigma) or DMSO vehicle for 45min.
For the establishment of stable cell lines (shRNA -15/14, shRNA scrambled,
pcDNA 3.1- and AS Uchl1DSINEB2), MN9D cells were seeded in 100-mm Petri
dishes and transfected with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instruction. Stable clones were selected by 500mM neomycin
(N1142, Sigma). HEK cells (Sigma) were cultured under standard condition in
DMEM containing 10% fetal bovine serum supplemented with antibiotics.
Transient transfections were done with Lipofectamine 2000 (Invitrogen). For all
experiments, S and AS plasmids were transfected at 1:6 ratio.
Animal handling. All animal experiments were performed in accordance with
European guidelines for animal care and following SISSA Ethical Committee
permissions. Mice were housed and bred in SISSA/CBM non-SPF animal facility,
with 12 h dark/light cycles and controlled temperature and humidity.Mice had ad
libitum access to food andwater. C57BL/6malemice (n5 5), 8–10weeks old, were
used for in situ hybridization experiments. Laser capture microdissection (LCM)
of dopaminergic neurons was performed on 8–10-week-old male TH-GFP/21-31
mice (n5 3). Intra-cardiac perfusions were done under total anaesthesia.
RACE and multiplex RT–PCR. The 59 UTR of antisense Uchl1 was amplified by
RACEPCR (GeneRacer, Invitrogen) byMN9D total RNAand cloned intopGEM-T
Easy vector (Promega).
qRT–PCR.Total RNAwas extracted fromcells andmouse tissue samples (adrenal
gland, cerebellum, cortex, olfactory bulb, striatum, ventral midbrain, heart, colon,
kidney, lung, lymph node, ovary, prostate, spleen, testis, uterus) using Trizol
reagent (Invitrogen) according to the manufacturer’s instruction. An RNA panel
of 20 different normal human tissues (pools consist of at least three tissue donors
with full documentation on age, sex, race, cause of death) was obtained from
Ambion (AM6000). All RNA samples were subjected to DNase I treatment
(Ambion). A total of 1mg of RNA was subjected to retrotranscription using
iScript cDNA synthesis kit (BioRad) and Real Time qRT–PCR was carried out
using SYBR green fluorescence dye (23 iQ5 SYBR Green supermix, BioRad).
TATA-binding protein (TBP) and RNA polymerase II (RPII) were used as house-
keeping genes to normalize different mouse and human tissues as tested by the
GeNorm program, version 3.5 (http://medgen.ugent.be/genorm/)27. GAPDH and
b-actin were used as normalizing controls in all the other qRT–PCR experiments.
The amplified transcripts were quantified using the comparative Ct method and
the differences in gene expression were presented as normalized fold expression
(DDCt). All of the experiments were performed in duplicate. A heatmap graphical
representation of rescaled normalized fold expression (DDCt/DDCtmax) was
obtained by using Matrix2png (http://www.bioinformatics.ubc.ca/matrix2png/).
A list of oligonucleotides used for qRT–PCR experiments is in Supplementary
Fig. 12.
LCM technology. For LCM, regions of midbrain from TH-GFP/21-31 mice were
dissected and incubated in 13 Zincfix solution for 6 h. They were then cryopro-
tected in 30% sucrose solution at 4 uC overnight, embedded in Neg-50 section
medium, snap-frozen and left to equilibrate in a cryostat chamber at 221 uC for
1 h before sectioning, as described earlier28. Cryostat 14 mm midbrain coronal
sections were thaw-mounted on Superfrost plus glass slides (Mezzle-Glasser)
and dopaminergic GFP1 cells were gathered via LCM and collected in microfuge
(PALM adhesive caps). RNA was immediately extracted using the Absolutely
RNA Nanoprep kit (Stratagene), eluted in RNase/DNase free water (Ambion)
and retro-transcribed.
Two-colour in situ hybridization.After perfusionwith 4% formaldehyde,mouse
brain was cryoprotected overnight in 30% sucrose. In situ hybridization was
performed on cryostat slices (16mm). Sense and antisense probes were generated
by in vitro transcription from the cDNAencoding the distal 600 bp ofmouseUchl1
cDNA and the last 1,000 bp of mouse antisense Uchl1. The probes for Uchl1 and
antisense Uchl1 were labelled with digoxigenin (DIG labelling, Roche) and biotin
(BIO-labelling mix, Roche), respectively. Incorporation of biotin and digoxigenin
was checked via a northern blot assay. In situ hybridization was performed as
described previously29. Slices were pre-treated with 3% hydrogen peroxide for
30min. Hybridization was performed with probes at a concentration of 1mgml21
(Uchl1) and 3mgml21 (antisense Uchl1) at 60 uC for 16 h. For biotinylated RNA
detection, streptavidin-HRP (Amersham Bioscience) was used (1:250) for 2 h in
TNB buffer (Tris HCl pH7.5 100mM,NaCl 150mM, 0.5% blocking reagent), and
signals were visualized using the TSA Cy3 system (Perkin Elmer) after washing in
TNT buffer (Tris HCl pH7.5 100mM, NaCl 150mM, 0.05% Tween-20). In situ
hybridization on DIG-labelled probe was performed with monoclonal anti-DIG
antibody after TSA reaction. To combine RNA in situ hybridization with immuno-
fluorescence, slices were incubated with anti-tyrosine hydroxylase (TH) antibody
1:1,000 (Chemicon). Signals were then detected with fluorescent dye-conjugated
secondary antibody goat anti-rabbit 405 and goat anti-mouse 488. Sections were
then washed, mounted with Vectashield (Vector lab) mounting medium and
observed with a confocal microscope (Leica).
Western blot. Cells were lysed in SDS sample buffer 23. Proteins were separated
in 15% SDS– polyacrylamide gel and transferred to nitrocellulose membranes.
Immunoblotting was performed with the following primary antibodies: anti-
UCHL1 (3524 Cell Signaling), anti-UXT (11047-1-AP Proteintech Group), anti-
p53 (1C12) monoclonal antibody (2524, Cell Signaling) and anti-b-actin (A5441,
Sigma). For the mTOR pathway: anti-phospho-p70 S6 kinase (Thr 389) (9234),
anti-phospho-4E-BP1 (Ser 65) (9451), anti-p70 S6 kinase (9202), anti-4E-BP1
(9452), anti-phospho-Akt (Ser 473) (3787) were all purchased from Cell Signaling.
Signals were revealed after incubation with recommended secondary antibodies
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conjugated with horseradish peroxidase by using enhanced chemiluminescence for
UCHL1 (WBKLS0500 Immobilion Western Chemioluminescent HRP substrate)
and ECL detection reagent (RPN2105, GE Healthcare).
Protein stability. MN9D cells were seeded in 12-well plates overnight and then
exposed to 100mgml21 protein synthesis inhibitor cycloheximide (CHX) for
15min and rapamycin 1mM or DMSO vehicle control for the following 45min.
Cellular fractionation. Nucleo-cytoplasmic fractionation was performed using
Nucleo-Cytoplasmic separation kit (Norgen) according to the manufacturer’s
instruction. RNA was eluted and treated with DNase I. The purity of the cyto-
plasmic fraction was confirmed by qRT–PCR on pre-ribosomal RNA.
Polysome profiles. Polysome profiles were obtained using sucrose density gra-
dients. MN9D cells were treated with 1mgml21 rapamycin for 35min, then with
100mgml21 cycloheximide for 10min prior to lysis in 150ml lysis buffer (50mM
Tris-HCl pH7.5, 100mMNaCl, 30mMMgCl2, 100mgml
21 cycloheximide, 0.1%
NP-40, 40Uml21 RNasin, protease inhibitors cocktail). Whole-cell extracts were
clarified at 4 uC for 10min at 15,000g. The equivalent of 5–10 absorbance units at
254nmof the clarified cell extract was layered onto 15–55% (w/v) sucrose gradient
(50mM Tris/acetate pH7.5, 50mM NH4Cl, 12mMMgCl2 and 1mM DTT) and
centrifuged for 3 h 30min at 39,000 r.p.m. in a Beckman SW41Ti rotor at 4 uC.The
gradient was pumped out by upward displacement and absorbance at 254nmwas
monitored using BioLogic LP software (Bio-Rad). One-millilitre fractions were
collected, 1ml Trizol reagent (Invitrogen) was added and RNA was extracted
following the manufacturer’s instructions. A fixed volume of each RNA sample
was then retro-transcribed and the percentage of mRNA in each fraction was
calculated as relative Ct value to total RNA.
Metabolic labelling.MN9Dwere used for analysis of translational rate. Cells were
seeded at sub-confluency in 6-well plates, and rapamycin (1mM) or DMSO sti-
mulations were performed for 45min. Cells were labelled with 5mCiml21 of
[35S]methionine (Amersham Pharmacia Biotech) for 45 min. Cells were lysed in
standard lysis buffer (Tris-HCl 20mM, NaCl 20mM, 0.5% Triton X-100) and
centrifuged. Supernatants were trichloroacetic-acid-precipitated and filtered on
glass fibre discs under vacuum. Discs were counted with scintillation fluid in a
b-counter. Total proteins were measured with the standard BCA method. Rate of
incorporation was expressed as CPM/total protein ratio (mean6 s.d.). Experiments
were done in triplicate.
Pulse labelling and immunoprecipitation. To monitor de novo protein syn-
thesis, HEK cells were transiently transfected with pEGFP plasmid (Clontech)
in combination with antisense GFP or empty control vector. After 24 h, medium
was replaced with methionine/cysteine-free DMEM for 1 h. Then, cells were
labelled with 100mCiml21 of [35S]methionine/cysteine (EasyTag, Perkin-Elmer)
for 1 h. Labelled cells were collected, lysed in RIPA buffer (150mMNaCl, 50mM
Tris pH8, 1mMEDTA, 1%NP40, 0.5% deoxycholic acid and 0.1% SDS) and used
for immunoprecipitation with anti-GFP antibody (Invitrogen) overnight.
Immune complexes were isolated with protein G-sepharose beads (Amersham)
and separated on 10% SDS–PAGE. Newly translated GFP was visualized by auto-
radiography. Densitometric analysis was performed on high-resolution images
with Photoshop-CS5. Normalization was obtained relative to input.
Northern blot. Polysome fractions were digested with 100mgml21 proteinase K
in 1% SDS and 10mg glycogen (Invitrogen) at 37 uC for 1 h. RNA was obtained by
phenol/chloroform extraction and re-suspended in formaldehyde/formamide
MOPS buffer. Samples were incubated for 5min at 65 uC before being loaded into
formaldehyde 1% agarose gel and run at 90V for 4 h at 4 uC. RNAwas transferred
onto Amersham Hybond-XL nylon membranes and UV-crosslinked. A radio-
labelledUchl1-specific complementary RNAprobe was transcribed from the same
plasmid used for in situ hybridization, performing the reaction in the presence of
50mCi ofa-32P-UTP (Perkin-Elmer). After treatmentwithDNase I (Ambion), the
labelled riboprobe was purified on RNeasy columns (Qiagen). Membranes were
pre-hybridized for 3 h at 65 uCwithNorthernMax prehybridization/hybridization
buffer (Ambion) supplementedwith 50mgml21 salmon spermDNA(Invitrogen),
andhybridizedwithUCHL1 riboprobe overnight at 65 uC in the samebuffer. After
extensive washes (most stringent conditions were 0.23 SSC/0.1% SDS at 65 uC),
membranes were exposed to autoradiography at280 uCwith intensifying screens.
Bioinformatic analysis. For the identification of additional translational activator
candidates, we searched for FANTOM3 full-length cDNAs that were non-coding
RNAs and overlap the 59 end of coding transcripts in a head-to-head configuration.
The filtered set of 8,535 FANTOM3 ncRNA transcripts described previously30was
used as our starting point. Genomic locations of these ncRNA transcripts and
RefSeq31 coding transcripts were extracted from the alignments in the UCSC
Genome browser32 to identify a set of 788 coding-sense–non-coding-antisense
pairs. ncRNAs were then checked by RepeatMasker to identify SINEB2-related
sequences (http://www.repeatmasker.org). This analysis reduced the number of
pairs to 127 protein-coding transcripts with overlap at the 59 end (60 with a sense
strand version of the repeat, 53 with an antisense version and 14 with both sense
and antisense versions).
Alignment of the SINEB2-related elements was then carried out using Clustalw
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). From this analysis the anti-
sense overlapping transcripts with a repeat most similar to the one of antisense
Uchl1 as well as in the same orientation were chosen for experimental testing
(antisense Uxt).
Statistical analysis. Statistical analyses were performed with paired two-tailed
Student’s t-test. Results are mean (n$ 3)6 standard deviation (s.d.).
27. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR
data by geometric averaging of multiple internal control genes. Genome Biol. 3,
RESEARCH0034 (2002).
28. Biagioli, M. et al. Unexpected expression of a- and b-globin in mesencephalic
dopaminergic neurons and glial cells. Proc. Natl Acad. Sci. USA 106,
15454–15459 (2009).
29. Ishii, T.,Omura,M.&Mombaerts,P.Protocols for two-and three-color fluorescent
RNA in situ hybridization of themain and accessory olfactory epithelia inmouse.
J. Neurocytol. 33, 657–669 (2004).
30. Nordstro¨m, K. J. et al. Critical evaluation of the FANTOM3 non-coding RNA
transcripts. Genomics 94, 169–176 (2009).
31. Maglott, D. R., Katz, K. S., Sicotte, H. & Pruitt, K. D. NCBI’s LocusLink and RefSeq.
Nucleic Acids Res. 28, 126–128 (2000).
32. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12,
996–1006 (2002).
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